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Chapter 1
Abstract
Parkinson’s (PD) is one the most common neurodegenerative movement disorder. The
complex etiology of the disease makes treatment difficult and although the past decades
of research have substantially increased our understanding of the disease, a completely
cure is still missing. Originally considered a sporadic disease, extensive genome wide
studies of PD patients has identified various genes which are now linked to PD. Out of all
the genes, the most prevalent is the leucine rich repeat kinase 2 (LRRK2). Mutations in
LRRK2 are now believed to cause the most common familial forms, and some sporadic
forms, of Parkinson’s. LRRK2 gene encodes for a large multidomain protein complex
LRRK2. Structurally LRRK2 is characterized by an unique modular architecture which
contains a GTPase and a kinase domain in the same complex and further surrounded
by several protein-protein interaction domains. Most of the pathologically important
LRRK2 mutations are clustered in the catalytic core of the protein, hinting that altered
GTPase and kinase activities play a crucial role in pathogenesis. There is a need to
unravel the structural mechanism that drive and modulate LRRK2 GTPase and kinase
activities for a better understanding of the disease mechanism and developing advanced
therapeutic strategies.
Another related but less scrutinized protein is LRRK1, the closest paralogue of LRRK2.
The domain organization of LRRK1 is very similar to LRRK2 and the expression profile
and cellular organization of both the proteins are also overlapping. However, irrespective
of these similarities, mutations in LRRK1 have not been genetically associated with
PD. This difference has stimulated various studies to understand the functional roles of
LRRK2 and LRRK1 and the link between the two. Structural and functional studies
on LRRK1 are not yet fully explored as LRRK2.
So far, it has been a challenge to isolate a sufficient quantity of intact, full-length LRRK2
and LRRK1 protein for structure determination. The available structural insights for
1
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LRRK2 come indirectly from the study of related proteins from the same family in lower
organisms. Crystal structures for the human LRRK2 ROC domain and bacterial ROC-
COR and kinase domain have been published so far. Although, these structures have
advanced our understanding of LRRK2 functions but are insufficient to fully address
their physiological relevance. Similarly, structural information about LRRK1 is minimal
with no 3D structures reported, neither of full-length protein nor of any of its domains.
In addition to continued effort to solve atomic models of individual catalytic domains
of LRRK2 and LRRK1 by X-ray crystallography, there is a need to elucidate structure
of full-length protein complex to delve deeper into the molecular functioning of the
whole protein, given that fact that surrounding the catalytic core, LRRK2 and LRRK1
has a number of protein-interaction domains which impart high degree of conformational
flexibility in order to accommodate different substrate to carry out the diverse functions.
The goal of this thesis is to solve the three dimensional structures of the homodimeric
complexes formed by full-length LRRK2 and LRRK1, respectively, analyzed by cryo-
electron microscopy (cryo-EM) imaging and computational single particle image anal-
ysis. This will enable for the first time to unveil the tertiary structure of the protein
complex. To realise the aim, the primary goal was to standardise the expression and
purification of full length LRRK2 and LRRK1 to produce adequate quantity and qual-
ity of proteins for structural determination. Constructs for the mammalian expression
of 3xflag tagged LRRK2 and 3flag tagged LRRK1 were expressed in human embryonic
kidney (HEK) 293 cells and subsequently used for affinity purification. Further, exten-
sive optimization of the purified protein for cryo-EM sample preparation was carried
out with the final aim to prepare homogenous sample for data collection by cryo-EM.
Chapter 3 includes the methods used for the expression and purification of LRRK2,
sample optimization for cryo-EM, data collection and single particle image processing.
Chapter 2 gives a general introduction to Parkinson’s, its various aspects and the role
of LRRK2 in Parkinson’s disease, followed by an introduction to LRRK2 and LRRK1.
In a second project, a novel method development is proposed to use liposomes as a tool to
study membrane proteins under buffer gradients by cryo-EM. Methods are described on
how to embed membrane proteins, such as voltage-gated potassium channels, into lipid
vesicles (liposomes), while altering the buffer conditions inside and the outside of the
buffer differently. This allows setting up a gradient such as pH, salt, ligands or membrane
potential across the liposome bilayer membrane. Chapter 4, describes these methods to
prepare liposomes, establish gradient, verify the presence of different buffers inside and
outside of the liposomes. The goal of the project is the provide a proof of concept for the
methods to be suitable for vitrification and image collection by cryo-EM. By optimising
different lipid of protein ratios, well ordered 2D crystalline liposomes reconstituted with
membrane protein were generated. These proteoliposomes can be processed by using
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a combination of electron crystallography and single particle processing routines. Al-
ternatively, for larger membrane proteins, tomography and subtomogram averaging can
also be utilised. Chapter 2 covers an introduction to electron microscopy, cryo-EM and
image processing, which is the common methodological tool used in both the projects.
Chapter 2
Introduction
2.1 Parkinson’s Disease
The history of Parkinson’s disease to be documented in literature dates back to 1817,
when British physician, James Parkinson (1755-1824) first described about this deadly
disease in his landmark article An Essay on the Shaking Palsy(Donaldson 2015). Later,
it was French neurologist Jean Martin Charcot (1825-1893), who made further contri-
bution to the understanding of the disease and named it after James Parkinson as an
honor. Today nearly 200 years later, we know Parkinson’s’ disease as a progressive
and chronic neurodegenerative disorder of the central nervous system (CNS) that af-
fects control of voluntary movement. It is one the leading neurodegenerative disorders,
second to Alzheimer disease and affects nearly ∼1% of the population over 55 years of
age and 10% for those over 80 years of age. Of all these cases, nearly 90% are sporadic,
where there is no known cause, while 10% are genetically linked either in an autosomal
recessive or autosomal dominant manner(Dauer and Przedborski 2003). PD is prevalent
all over the globe; however, the occurrence of disease is slightly lower in women than
in men(Shulman 2007). According to the statistics in Europe, the estimated prevalence
and incidence rates of Parkinson‘s Disease was approximately 108 to 257/100,000 and 11
to 19/100,000 per year, respectively. Though a lot of progress is made in understanding
the neurobiology of PD, the diagnosis of PD still remains a major challenge. There are
treatments available to lessen the symptoms but at present PD is incurable.
2.1.1 Symptoms of Parkinson’s disease
The symptoms of Parkinson’s disease can be broadly divided into two types: motor
symptoms and non-motor symptoms. The fundamental motor symptoms in PD are
4
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Figure 2.1: Loss in Substantia Nigra. (Image source: A.D.A.M Inc, 2011)
rigidity, bradykinesia and postural instability. Regardless of the etiology, they are all
caused by the loss of dopaminergic neurons in the substantia nigra (Figure 2.1). The
most evident of the motor symptom in PD is tremor, which has a characteristic ap-
pearance in PD patients. It is one of the most common symptoms found in 70% of the
PD patients. The tremor starts with the hands, with a back and forth motion of the
thumb and the forefingers(Jankovic 2008). The second most common symptom in PD
patients is Rigidity, which results from the stiffness and lack of movement in a body
part such as ankles, hips, knee, shoulders and neck. Bradykinesia denotes slowness in
movement or in some patients can also turn into akinesia that means complete absence
of movement. This is also a common symptom and a characteristic clinical feature of
PD. Over time patients lose the ability to execute rapid, multi-step movements. The
last common motor symptom of PD is postural instability that occurs due to the loss
of postural reflexes. The patients suffer from impaired balances, unsteady posture and
frequent falls(Dauer and Przedborski 2003). Apart from these major symptoms, other
motor dysfunctions are also common in PD. These include feet shuﬄing, reduced arm
swing, and abnormal forward-flexed posture. Abnormal muscle contractions are also
common in PD patients that can cause severe fatigue and reported in estimated 50%
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of patients. Speech disorder are also routinely observed and characterised by facial la-
ryngeal bradykinesia and rigidity which causes difficulty in finding words(Matison et al.
1982; Critchley 1981). Complications related to respiratory abnormalities are also seen
in PD patients(Biousse et al. 2004). In addition to motor symptoms, usually in the later
stages of the disease, PD patients suffer from a variety of non-motor symptoms. These
non-motor symptoms are predominantly a result of the loss of non-dopaminergic neu-
rons. These include problems with sleep cycles, cognition abilities and behaviour. These
symptoms affect the quality of life of the PD patients and are most troublesome(Hely
et al. 2005). Among these the most prevalent non-motor symptom is sleep disturbance,
which occurs in nearly all PD patients(Jahan et al. 2009). Sleep disturbances include
other related symptoms like insomnia, rapid eye movement, sleep deprivation, sleep ap-
nea and parasomnias. It has been suggested, sleep disorders in patients could hint to be
a precursor of early onset PD(Schenck et al. 1996; Plazzi et al. 1997). Cognition dis-
abilities and neuropsychiatric disorders like depression and anxiety are also common PD
symptoms(Aarsland et al. 2007). There is a propensity of a quarter of all PD patients
progressing to dementia in the advance stages of the disease, which involves slowing
of thoughts and memory difficulty and behavioral regulation. Delusions, paranoia and
hallucinations may also develop in severe PD cases(Frank 2005);(Frank 2005; Levin and
Katzen 2005). Mental disorders, anxiety and mood disorders are also linked to PD.
These have been related to a affected dopamine metabolism(Leentjens 2004; Nuti et al.
2004).
2.1.2 Etiology
Etiology is a branch of medical science concerned with the causes and origins of a disease.
Parkinson’s disease is a very complex disease and its etiology is still unclear. Most PD
patients have idiopathic Parkinson’s disease i.e. having no specific known cause for
the disease. However, recently many cases have been attributed to have genetic factors
involved. There are other risk factors such as age, environmental toxins and pesticides
that have been linked with the risk of developing PD.
2.1.2.1 Aging
Age is the major risk factor for PD. Aging can cause irreversible damage to the cells,
weaken repairing capacity of the cells and predispose people to neurodegenerative dis-
eases(Hindle 2010). Within a population, the percentage of affected individuals rises
from 1% (65 years of age) to 5% (85 years of age). Though, there is not a clear known
reason for a gender factor involved in the PD but the occurrence of PD patients in males
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is slightly more than the females. One study suggested the protection of dopaminergic
neurons by female hormone estrogen(Shulman 2007). Geographic distribution too does
not play a big role in PD, although PD cases in Hispanic and non-Hispanic American
people is slightly higher than in African Americans and Asians(Van Den Eeden et al.
2003). The age also plays a role at onset of PD, which has a wide distribution. Although,
the mean age at onset is 55 years, disease onset can also occur at what is termed as
a juvenile onset which happen before 21 years of age; or an early onset occurring be-
tween 21 and 50 years of age; or lastly as late onset which is beyond 50 years(Dauer and
Przedborski 2003).
2.1.2.2 Environment
Environmental factors have been for decades thought to be the most prominent cause
of PD. Several years of research have identified specific environment agents like neuro-
toxins and viruses responsible for PD. In the early 1980’s, one such environmental agent
was discovered, methyl-4-phenyl-1,2,3,6- tetrahydropyridine or MPTP for short. MPTP
is a prodrug to the neurotoxin MPP+, which have been known to cause permanent
symptoms of PD. While MPTP itself has no psychoactive effects, the compound may be
accidentally produced during the 1-methyl-4-phenyl-4- propionoxypiperidine (MPPP)
synthesis. MPPP is a synthetic opioid drug with effects similar to those of morphine
and pethidine(Langston et al. 1983). MPTP has been demonstrated for the toxicity
of dopaminergic neurons in mouse models that further confirmed its specific toxicity to
PD(Teismann and Ferger 2001). MPTP has been since actively used to study disease
models in various animal studies.
Another chemical that has been linked to induce a toxic model in PD is Rotenone.
Rotenone is a widely used insecticide and fish poison which is highly lipophilic and
readily gains access to all organs(Talpade et al. 2000). Like MPP+, Rotenone can
bind to the same site of mitochondrial complex I and can inhibit the electron transport
chain(Betarbet et al. 2000). Other heavy metals and industrial toxins have also been
examined for their role as a potential environmental causes of PD but no causal link has
been identified. In addition to chemical environmental factors linked to PD as inducing
agents, viruses have also been identified to cause PD. In 1918 influenza outbreak caused
post-encephalitis PD in a large population. A recent study reported that certain strains
of H5N1 avian flu virus infection can cause higher susceptibility to PD(Jang et al. 2009).
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2.1.2.3 Genetics
A lot of early research on PD identified these environmental factors associated and
helped cracking the mystery of the disease Etiology, however, recent research interests
have now been shifted to the genetics factors involved in PD. The shift is a result of im-
provements in the molecular and genetic research technologies in recent decades. Today,
it is estimated that 5-15% of all PD cases have a genetic component involved, show-
ing both autosomal recessive and dominant modes of inheritance. If the age of disease
onset, family history of PD and special ethnic origin are considered as well, then the
percentage can go as high as 75%(Klein and Schlossmacher 2006; Lcking et al. 2000).
Several studies have repeatedly given evidence to support that genetics risk factors play
an important role in PD. For instance, after age; as the first predictor for high risk of
PD, family history of PD is the second best predictor(Semchuk et al. 1993). These
reports which study the family history of PD patients reveals that for idiopathic PD
patients, it is very likely they will have a positive family history and there are dou-
ble chances for the individuals to develop the disease that have a first degree relative
with PD(Marder et al. 1996; Lazzarini et al. 1994). More insights on the genetic link
between PD patients comes from the large cross-sectional twin studies, which have iden-
tified major differences in concordance rates between the monozygotic twins and the
dizygotic twins in early onset PD but absent in late onset PD(Wirdefeldt et al. 2004).
These studies has shed more light on the genetic risk factors involved in PD but they
been proven incapable to detect the incomplete penetrant mutations(Simon et al. 2002).
Results from another longitudinal study that used 18F-dopa positron emission tomogra-
phy (PET) to study dopaminergic functions in twins found 75% disease concordance to
occur in monozygotic twins, while for dizygotic twins, it was 22%, regardless of age at
onset(Piccini et al. 1999). Together, these data suggests that the genetics susceptibility
in PD is much greater than previously anticipated. These genetic contributions might
not be detected straightway because sometime patients do not have clear family history
or the mutated gene has low penetration. Other factors like environment exposure and
genetic predisposition can also play a role.
2.1.3 Pathology
There are two pathological conditions in PD that are considered hallmark. First is
the loss of nigrostriatal dopaminergic neurons in the midbrain and the second is the
formation of intraneuronal cytoplasmic inclusions in the remaining dopaminergic neurons
located in substantia nigra pars compacta (SNpc), these are termed as Lewy bodies
(Figure 2.2)(Dauer and Przedborski 2003). There are four major dopamine pathways
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located in the brain, nigrostriatal pathway is one of them and is primarily involved in the
control and production of voluntary response. This pathway comprises of dopaminergic
neurons and their cell bodies are located in SNpc region of the brain. The SNpc contains
large amount of a substance called neuromelanin, which gives the region its characteristic
pigmented appearance. Macroscopic alterations can be noticed on cut surfaces of the
brainstem, where neuronal loss can be inferred from a depigmentation in the SNpc. At
the start of the disease symptoms, around 60% of the dopaminergic neurons in the SNpc
region have already started degenerating(Marsden 1983). Frederic Lewy (1885-1950)
was the first neurologist to observe Lewy bodies in 1912. Lewy bodies are considered
characteristic indicator of PD but they are also well known pathological features in
other neurological disease such as dementia with Lewy bodies (DLB), Hallervorden-Spatz
syndrome, Alzheimer’s disease and Down’s syndrome(Neumann et al. 2000; Giasson et
al. 2000; Spillantini et al. 1998). Even in 10-15 % of patients over the age of 65, dying
without any clinical or pathological neurological illness, Lewy bodies are found in the
autopsy of neurons of the SNpc(Gibb and Lees 1988; Braak et al. 2003).
Figure 2.2: A single Lewy Body present in a pigmented neuron from the substantia
nigra Cunningham et al., 2015)
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Lewy bodies are spherical, intraneuronal masses containing a variety of proteins includ-
ing α-synuclein, synphilin-1, ubiquitin proteasome system (UPS), heat shock proteins
and tau proteins(Ishizawa et al. 2003; Olanow et al. 2004). Lewy bodies have been
divided into two morphological types: classical (brainstem) Lewy bodies and cortical
Lewy bodies.
Classical Lewy bodies are primarily composed of α-synuclein and are characterised by
10um wide dense core which is surrounded by a halo looking appearance. While, cortical
Lewy bodies have a more homogenous appearance without having a distinctive core
and halo around them(Forno 1996). The formation of Lewy bodies is still unclear,
though there are several hypotheses to explain the mechanism. Recent findings suggest
Lewy bodies are related to aggresomes and functions as a cellular scrapyard of degraded
ubiquitinated proteins in response of proteolytic stress. It is still not fully understood
whether Lewy bodies have a detrimental role in causing neuronal death or are simply a
byproduct of neurodegeneration.
Braak’s staging system was recently created by Braak and colleagues. They created
a neuropathological staging procedure that allows differentiating between initial, inter-
mediate, and final stages of PD-related lesions. The early changes are defined in the
Braak stage 1 and Braak stage 2 and they are generally pre-symptomatic, seen mostly in
medulla oblongata and olfactory bulb. In Braak stages 3 and 4, cell death and inclusion
formation begins and protein aggregation is noticed in areas of the midbrain and basal
forebrain. The final stages 5 and 6 are characterized by progressive neurodegeneration
in the cerebral cortex and in the other affected regions of the brain(Davie 2008; Braak
et al. 2006). Among all the Braak’s stages, the manifestation of clinical features of PD
occurs during stage 3. In PD patients, the percentage of dopamine depletion in putamen
region is 80%, while the neuronal loss in substantia nigra pars compacta at disease onset
is 60%(Lang and Lozano 1998). This loss of neurons is responsible for the depigmenta-
tion in substantia nigra pars compacta, which is the classic neuropathological hallmark
in PD(Marsden 1983). The depletion of dopaminergic neurons within the caudate and
SNpc neighbouring projection sites are comparatively less(Uhl et al. 1985; Price et al.
1978). Parkinsonism is a term used very often in PD pathology to denote the broader
other PD like neurological disorders like dementia with Lewy bodies (DLB), progressive
supranuclear palsy (PSP) and multiple system atrophy (MSA). These account for more
than 80% of cases and share similar clinical symptoms of PD but not necessarily the
neuropathological features of PD.
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2.1.4 Diagnosis
Diagnosis of Parkinson’s disease is often very difficult. The symptoms of PD overlap
with symptoms of other neurological disorders, especially at the early stages. This
makes PD difficult to diagnose and physicians are required to have broad experience
in neurological disorders. Early detection of PD is very difficult and most of the times
early signs and symptoms of the disease are dismissed as the normal effects of aging
or other disease conditions. It is estimated that around 40% of patients may not be
diagnosed for PD at all and a quarter of patients are often misdiagnosed.(Gelb et al.
1999). At present, there are no laboratory tests that could be used to diagnose PD, so the
only diagnosis possible is typically based on the medical history, interviews, counseling
and neurological examination of the patients together with regular laboratory tests like
electroencephalogram (EEG), computed tomography (CT), magnetic resonance imaging
(MRI) and blood tests. These techniques are not used to directly diagnose PD but more
useful to rule out other diseases that can be secondary causes of parkinsonism, such
as vascular pathology, basal ganglia tumors, and hydrocephalus(Brooks 2010). There
are two common clinical tools that are used in the diagnosis of PD and determine its
severity: the Hoehn and Yahr Scale and the Unified Parkinson’s Disease Rating Scale
(UPDRS)(Goetz 2006). During these diagnoses and assessment physicians enquire about
characteristic symptoms of PD such as resting tremor, rigidity, bradykinesia and postural
instability. The presence of at least two of these motor symptoms confirms the diagnosis
of PD. The patient undergoing the examination is also asked to perform a series of
behavior test, including walking around and sitting down to confirm diagnosis. Though
these test help in the timely detection of the disease, they are often considered not very
definitive.
2.1.5 Treatment
There is currently no cure for PD. The medication and treatments available only help
to relieve the symptoms and improve the quality of life of PD patients. There has
been considerable progress in understanding the etiology, pathogenesis, and pathology
of PD which have resulted in the development of numerous treatments for this chronic
disorder. Current treatment practices, however, only target the dopaminergic features
of the disease to alleviate motor symptoms which prevents these treatments to be proven
fully satisfactory. There is yet an absence of any therapeutics that either slow progression
or completely stop the neurodegeneration in PD patients.
The most common medication practice in PD is to counteract the depletion of dopamine,
therefore most medications function by increasing the dopamine supply in brain. There
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are different kinds of drugs known that increase the level of dopamine in the brain, these
include: Levodopa (L-dopa), Catechol O-methyltransferase (COMT) inhibitors, MAO-B
inhibitors and dopamine agonists. Out of these Levodopa remains the most commonly
used drug in PD treatment. Levodopa is a dopamine precursor that was first introduced
in 1950s. In contrast to dopamine, Levodopa can cross the blood brain barrier easily
and then converted into dopamine by the amino acid decarboxylase (AADC) enzyme
also known as dopa- decarboxylase (Figure 2.3). However only a small fraction of lev-
odopa enters dopaminergic neurons, while most of the remaining drug is metabolized
to dopamine in the peripheral nervous system. This can cause a wide variety of side
effects in PD patients. To curb the unwanted side effects of Levodopa in the periph-
eral nervous system, it is supplemented with a peripheral dopa-decarboxylase inhibitor
(DDCI)(Radad et al. 2005). Another class of drugs that are usually co-administered
with Levodopa are Catechol O-methyltransferase (COMT) inhibitors (e.g., entacapone
and tolcapone) which functions by blocking the breakdown of Levodopa. The efficacy to
these PD medications can be dramatically positive in the early stages of treatment. How-
ever, the response of medications starts fading with the progress of disease and eventually
patients lose the responsiveness to the medication. So, both DDC and COMT inhibitors
aids in increasing the amount of levodopa that brain receives. Once in the brain, there
is another problem, the dopamine that is being generated by conversion of Levodopa
can further be metabolized and broken down into other compounds. Here, monoamine
oxidase-B (MAO-B) inhibitors (e.g., selegiline and rasagiline) comes to rescue and pre-
vents the formation of these inactive dopamine metabolites and hence improving motor
function in PD patients. They do this by inhibiting the enzyme MOA-B that catalyse
the breakdown of Dopamine. Another class of drugs used in PD treatments is agonists
of Dopamine like pramipexole (Mirapex) and ropinirole (Requip), these are capable of
mimicking the effect of dopamine on neurons. But these drugs are only used temporarily
as they are capable of desensitizing dopamine receptors and can cause long-term prob-
lems in patients if taken routinely(Koller and Rueda 1998). Apart from these major
drugs for PD treatment, several naturally occurring products are known to be beneficial
in reducing PD symptoms. Natural anti-oxidants like vitamin E, vitamin C, Coenzyme
Q10 and NADH have been used with some degree of relief in PD patients. Apart from
these drugs, which are targeted towards motor symptoms, there are other pharmacolog-
ical strategies that can be used to treat non-motor symptoms of PD. These include the
usage of tricyclics and selective serotonin reuptake inhibitors (SSRIs) to treat depres-
sions that is common in PD patients(Lieberman 2006). Clozapine is routinely known to
significantly improve psychosis in patients when used in low doses(Pollak et al. 2004).
To treat other non-motor symptoms in PD patients like sleep imbalance, speech problem
etc. non-pharmacological strategies and counseling is employed(Freedom 2007). Occu-
pational, speech therapies are often known to improve the overall quality of life for PD
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patients(Boelen 2007).
Figure 2.3: Dopamine biosynthesis and its regulation by various drugs. (Youdim et
al., 2006)
When drugs are not able to control the symptoms or produce harmful side effects in
PD patients, surgical treatments are considered. Though surgery is not a cure to treat
PD, it can often help in relieving pain and PD symptoms. Of all the known PD related
surgeries, the most commonly performed is deep brain stimulation (DBS). DBS uses
electrical impulses to stimulate targeted areas in the brain such as subthalamic nucleus
(STN) and the globus pallidus interna (GPi)(Plaha et al. 2006; Benabid et al. 2009). In
this way, the tissues are not physically destroyed and still inactivated to reduce the PD
symptoms. In DBS, patients are implanted with a impulse generator which is connected
by wires to the target brain region via electrodes. Once activated, these electrodes
can inactivate the tissues by using continuous electrical pulses.(Kern and Kumar 2007;
Hammerstad and Hogarth 2001). Owing to these advantages, DBS is the most preferred
surgical method used in PD but there are still few side effects that are associated with
DBS. These include cognitive disability, hallucination, bleeding in the brain, depression
etc.. Nevertheless, DBS has proved to be an effective treatment and helped more than
70% of PD patients to a reduce medications and significantly improved their motor
symptoms.
Other surgical methods that are used in PD treatments in early days and not used very
often now a day, are both focused on removing the areas in brain which are thought to
be involved in PD symptoms. These two areas of brain are globus pallidus and thalamus
and the surgeries performed to remove part of these two brain areas are pallidotomy and
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thalamotomy, respectively. Globus pallidus is the part of the brain that is believed to
become overactive in PD patients and serves to slow body movement, while thalamus is
thought to be responsible for the abnormal brain activity that causes tremors(Kern and
Kumar 2007; Hammerstad and Hogarth 2001).
Another area of PD treatment that has been very recently proposed and still under active
development is gene therapy. The general idea of gene therapy is to create and transplant
specialised cells that are capable of producing dopamine in the PD patients. So far the
approach is to use adeno-associated viral vector serotype 2 (AAV2) as a vector platform
to transfer the genes coding for enzymes such as aromatic L-amino acid decarboxylase
(AADC). This therapy can restore the normal levels of AADC in the striatum thereby
catalysing more conversion of levodopa to dopamine and reducing levodopa induced
dyskinesia in PD patients(Forsayeth et al. 2010). The proposed plans are still in early
stages of pharmaceutical trials and viral gene delivery is still not FDA approved due
to the overlying safety concerns. Therefore it’s a long way for gene therapy to be used
widely in PD treatments.
2.1.6 Genes associated with PD
Traditionally, PD has been considered a sporadic disease. However, according to the
statistics, around 15% of individuals suffering with PD are reported to have a first-
degree relative who already has the disease(Samii et al. 2004). Over the past two
decades, advancement in the genetic and molecular techniques has revealed startling
genetic link to PD. It is now estimated at least 5% -15% of all known PD cases are
caused due to a mutation in one of several specific genes which are transmitted in
either an autosomal-dominant or autosomal-recessive pattern(Funayama et al. 2002;
Lesage and Brice 2009). Extensive genome wide studies have identified 11 regions of
human genome that are linked to PD. Large scale gene mapping of PD affected families
have further extended our understanding and identified seven major genes which are
responsible for PD. These genes are: SNCA, UCH-L1, MAPT, PRKN, DJ1, PINK1 and
LRRK2. Out of these, α-synuclein (SNCA) was the very first to be associated with the
autosomal dominant form of PD(Krger et al. 1998; Au and Calne 2005; Polymeropoulos
et al. 1997). α-synuclein is a 140 amino acids protein that is primarily found in the
human neuronal tissues and also forms the major constituents of Lewy bodies. The α-
synuclein gene was the very first gene to be discovered as a causative factor for PD, later
it was reported that the occurrence of this gene mutation is very rare(Farrer et al. 1998).
Higher levels of α-synuclein due to the genomic multiplication of α-synuclein gene are
also believed to be linked to familial PD and there has been studies that show a direct
relationship between the gene multiplication and disease onset age, progression and
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phenotypic severity(Mueller et al. 2005). The exact role of the α-synuclein mutations
in PD and their biochemical mechanism is still not clear. It is generally believed that
the aberrant dopamine metabolism, protein degradation dysfunction and ER stress are
implications in the pathogenesis of PD linked with α-synuclein mutations(Corti et al.
2005).
Table 2.1: List of all known genes, loci and proteins associated with Parkinson’s
disease.
Locus Gene Protein Model
Park1 SNCA α-synuclein Autosomal dominant
Park2 PARK2 Parkin Autosomal recessive
Park3 Unknown Unknown Autosomal dominant
Park4 SNCA α-synuclein Autosomal dominant
Park5 UCHL1 Ubiquitin c terminal hydrolase Autosomal dominant
Park6 PINK1 Pten-induced putative kinase 1 Autosomal recessive
Park7 PARK7 DJ-1 Autosomal recessive
Park8 LRRK2 Leucine-rich repeat kinase 2 Autosomal dominant
Park9 ATP13A2 Lysosomal type 5 ATPase Autosomal recessive
Park10 Unknown Unknown Risk locus
Park11 GIGYF2 GRB interacting GYF protein 2 Autosomal dominant
Park12 Unknown Unknown X-linked
Park13 HTRA2 HTRA serine peptidase 2 Autosomal dominant
Park14 PLA2G6 Phospholipase A2 Autosomal recessive
Park15 FBXO7 F-box only protein 7 Autosomal recessive
Park17 VPS35 Vacuolar protein sorting 35 Autosomal dominant
Park18 EIF4G1 Eukaryotic translation initiation factor 4 gamma 1 Autosomal dominant
Park19 DNAJC16 DNAJ/HSP40 homolog subfamily C member 6 Autosomal recessive
- SNCA α-synuclein Risk locus
- LRRK2 Leucine-rich repeat kinase 2 Risk locus
- GBA Glucocerebrocidase Risk locus
Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is another gene that has been linked
with PD. It was identified as a single missense mutation (Ile93Met) in a sibling pair
with autosomal-dominant PD(Leroy et al. 1998). Later, another polymorphism S18Y
was identified in the UCH-L1 gene which was also associated as a PD risk factor mu-
tation(Elbaz et al. 2003). UCH-L1 is highly abundant protein, which is specific to
neurons and also found in Lewy bodies of sporadic PD patients and is also known to
promote accumulation of α-synuclein(Lowe et al. 1990). This is the reason anti-UCH-
L1 antibodies are widely used in staining of Lewy bodies. This protein belongs to the
family of deubiquitinating enzymes and functions in the hydrolysis of long ubiquitin
polymers(Wilkinson et al. 1989; Rodriguez-Viciana et al. 1997).
Mutations in the parkin gene have been identified as one of the most common cause of
early-onset parkinsonism and were reported for the first time in several Japanese fam-
ilies with autosomal recessive juvenile parkinsonism(Kitada et al. 1998). Since then, a
number of other mutations have been reported for this gene. It is the second largest
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gene known and encodes for the parkin protein on chromosome 6q34. It is a compo-
nent of the large E3 ubiquitin ligase and responsible for transferring activated ubiquitin
molecules to substrate targeted for UPS mediated protein degradation(Schlossmacher
and Shimura 2005). Loss of function in parkin is a major cause of early onset PD and
many parkin mutations have been reported, which affect the wild type parkin cellular
localization, disruption of mitochondrial integrity and cellular homeostasis(Wang et al.
2005; Cookson et al. 2003; Narendra et al. 2008).
Mutations in the DJ-1 gene were identified in 2003 in two families with autosomal
recessive PD in the early onset stage(Bonifati et al. 2003). Pathogenic mutations in DJ-
1 are rare and known early-onset PD cases are less than 1 percent(Abou-Sleiman et al.
2003). The protein expression is mostly localized in neuronal and glial cells in the brain.
Though the precise function of the protein remains elusive, it has been postulated to
play a role in oxidative stress response and have also been linked with the mitochondrial
impairment(Bandopadhyay et al. 2004).
In a study of three families with early onset autosomal recessive PD, mutations in the
PINK1 gene were identified which, were previously linked with the PARK6 locus(Valente
et al. 2004). PINK1 is a mitochondrial serine/threonine-protein kinase. Not a lot
is known about the protein’s cellular functions, but it has been suggested to play a
protective role during stress induced mitochondrial dysfunction(Gandhi et al. 2006;
Silvestri et al. 2005). There have been few mutations identified for this protein which
show impaired protein folding and kinase activity(Beilina et al. 2005). Similar to Parkin,
for PNK1 as well, loss of function mutations are believed to be a cause of early onset
PD and suggested that PINK1 may act upstream of Parkin in common pathological
pathways(Wang et al. 2011).
Another gene that has been linked with PD is the microtubule associated protein
tau (MAPT). Protein aggregation resulting from the neurofibrillary tangles consisting
mainly of tau proteins has been known to occur in PD. There may be occasional aggre-
gation of α-synuclein as well. MATP mutations have been reported in frontotemporal
dementia with Parkinsonism linked to chromosome 17 (FTDP-17) and also in atypical
PD without Lewy body formation. LRRK2 is the most recently identified gene for PD
and the next section describes it in detail.
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2.2 LRRK2
2.2.1 Introduction
In 2004, a locus located on the chromosome 12q12 was linked to autosomal dominant PD
in a large Japanese family, the Sagamihara. The identified locus is termed as PARK8
and was further confirmed to be linked with PD by genomic studies of other families be-
longing to diverse nations like United States, China and European countries(Funayama
et al. 2005; Paisan-Ruiz et al. 2005; Shen 2004; Zimprich et al. 2004). The gene that is
associated with PARK8 and linked with parkinsonism was identified as LRRK2(Paisan-
Ruiz et al. 2004). LRRK2 is also known by another name, dardarin, which comes from
dardara (meaning tremor in Basque language). LRRK2 gene comprises of a total of 144
kilobases containing 51 exons. Mutations in the LRRK2 gene have since the time of its
discovery proven to be the most common cause of familial PD(Satake et al. 2009). The
protein encoded by the gene is also called LRRK2 and has an approximate molecular
weight of 286 kDa.
Figure 2.4: Domain organization of LRRK2. Predicted domains are depicted with
different colors and they are also color coded according to their function. Grey line
denotes those protein protein domains which are implicated in protein-protein inter-
actions, which include : armadillo repeats(ARM), ankyrin repeats(ANK), leucine-rich
repeats(LRR) and WD40 repeats (WD40). The domains involved in the GTPase func-
tion are depicted in pink color and includes the Ras Of Complex proteins (ROC) and
C-terminal Of ROC (COR) domains and the red line denotes the Kinase domain (KIN)
2.2.2 Domain structure
LRRK2 is a member of the protein family known as ROCO. This multi-domain protein
family is characterised by a unique structural/functional feature, there is a Roc (Ras
of complex protein) domain which is immediately followed by a COR (C terminal Roc)
domain forming what is termed as a Roc-COR tandem.(Marin et al. 2008; Bosgraaf and
Van Haastert 2003). ROCO proteins are found in all forms of living organisms ranging
from prokaryotes, metazoans, plants and mammals. To date, at least 40 members of
the ROCO protein superfamily has been identified(Bosgraaf and Van Haastert 2003).
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Apart from the characteristic Roc-COR domain, LRRK2 comprises several independent
domains including a kinase domain, a C-terminal WD30 domain and three protein-
protein interaction domains like armadillo (ARM), ankyrin repeats (ANK), leucine-rich
repeats (LRR) (Figure 2.4). Most of the pathologically important mutations are clus-
tered in the catalytic core of this protein comprising of Roc-COR and Kinase domain,
hinting that LRRK2 might function as a upstream central modulator in various cell sig-
nalling pathways which are involved in the proper functioning of brain. The presence of
both protein-protein interaction domains together with enzymatic domains in the same
protein suggests further that LRRK2 might serve as a scaffolding protein for assembly
of other proteins in multiprotein signalling cascades.
2.2.2.1 ARM domain and ANK domain
The N-terminal of LRRK2 begins with three repeat domains. The first one is Armadillo
Repeat (ARM) domain and is composed of a repeating 42 amino acids motif organised
in typical three α-helixes pattern that was first identified in the Armadillo protein in
Drosophila, from which it got its name (Figure 2.5, top). The human homologue of the
Drosophila Armadillo protein is β-catenin. The Armadillo domain is known to form a
versatile molecular platform and facilities interaction with various proteins(Tewari et al.
2010). All the structures proposed for these repeating domains come from structural
modeling and bioinformatics tools and they differ in their claims slightly(Cardona et
al. 2014; Mills et al. 2012). The repeat size, number and likely boundaries of these
predicted structural domains differ in different studies and therefore, there is still a need
to validate the claims unambiguously with real experimental structure.
The next domain in LRRK2 is called Ankyrin (ANK) domain and is composed of seven
ankyrin repeats. Each Ankyrin repeat has a characteristic structure, which is composed
of two antiparallel helices, which is followed by a β-hairpin loop. The ANK repeats
stack together and form a slightly curved structure (Figure 2.5, bottom). Ankyrin
repeats are also found in various bacterial as well as other eukaryotic proteins and form
functional, structural motifs in signalling proteins, transcription factors, cytoskeletal
proteins etc(Mosavi et al. 2004). As with the ARM domain, the structural model for
the ANK domain comes from homology modelling, using known protein structures with
similar domains for prediction and they differ in the usage of bioinformatics software
and tools(Cardona et al. 2014; Mills et al. 2012).
Chapter 2. Introduction 19
Figure 2.5: Predicted model and limit definition of LRRK2’s ARM (top) and ANK
(bottom) domains. ( Cardona et al., 2014)
2.2.2.2 Leucine-rich repeat (LRR) domain
The third repeating domain is the Leucine-rich repeat (LRR) domain. LRRK2 contains
13 of the namesake LRRs. LRR is a very conserved domain that is found in variety of
proteins in all organisms responsible for intra and inter cellular protein-protein interac-
tions. These repeats are usually 20-29 amino acids long and usually present in tandem.
Individual repeats form a structure of β-α units, each unit comprising of a β-strand and
an α-helix, held approximately parallel to each other. Several of such repeats are ar-
ranged consecutively and parallel to a common axis, forming an arch-like structure(Kobe
and Kajava 2001). There are several mutations in LRR that has been linked to PD,
signifying the importance of the LRR domain in the disease pathogenesis. There are
several pathogenic mutations (R1067Q, S1096C, and S1228T) and one disease segragat-
ing mutation (I1122V) known to be lying within the LRR domain, all these mutations
are located at the surface and postulated to be involved in protein binding. Recently, a
study by Van Craenenbroeck and colleagues focussed on the structural analysis of LRR
by expressing and purifying LRR in bacteria. The study revealed the presence of 18%
α-helices and 21% β-sheets (Figure 2.6)(Vancraenenbroeck et al. 2012).
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Figure 2.6: Ribbon representation of the predicted model of LRR domain of LRRK2
(residues 983 to 1317) (Vancraenenbroeck et al., 2012)
2.2.2.3 Ras of complex protein (Roc) domain
The Roc domain of the ROCO protein family is a characteristic feature of the family
and stands out among other members of Ras superfamily of small GTPases(Bosgraaf
and Van Haastert 2003). The Ras related small GTPase protein superfamily has five
subfamilies within: Ras, Rho, Rab, Sar/Arf and Ran. They play a variety of biological
roles. These Ras-related GTPases functions as molecular switches in the cell in order
to regulate the diverse function that they perform. They serve by switching between
the GTP-bound and GDP-bound conformations. The GTP-bound state is the active
conformation where the GTPases are cable of binding to the substrate or another protein,
which further evoke downstream reactions. There are additional guanine nucleotide
binding proteins which are specific of each GTPase subfamily and regulates to enhance
GTP-binding and enhance downstream signaling. An example is of guanine nucleotide
exchange factors (GEFs) which facilitate GTP-binding while GTPase activating proteins
(GAPs) enhance the rate of GTP hydrolysis to terminate signalling, and there is another
class of protein called GDP dissociation inhibitors (GDIs) which are known to inactivate
the GDP-bound protein(Takai et al. 2001)
The Roc domain of LRRK2 shares the most sequence homology with the Rab subfamily
of Ras-related GTPases. The Rab GTPases are fairly conserved in the entire living
organism from yeast to higher eukaryotes. In the human genome, there are a number
of genes linked with Rab GTPases. These protein from different organism differ from
each other mostly in their C-terminal, which have been implicated to be involved in
cell signalling, whereas the residues which are involved in guanine nucleotide binding
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are mostly conserved(Chavrier et al. 1991). From X-ray crystallography experiments,
we know that the Rab GTPases share a structure that is very similar to the structure
of all small GTPases of the Ras superfamily. The general structure is composed of six
stranded beta sheets that are surrounded by five alpha helices. The five loops that
connect these beta strands and alpha helices are responsible for binding of guanine
nucleotide and magnesium ions(Stenmark and Olkkonen 2001). Out of these five loops,
four are conserved in Roc domains, including the amino acids residues, which are involved
in the binding and hydrolysis of GTP. The catalytic mechanism of Rab proteins is very
similar to that of other Ras related GTPases.
Figure 2.7: Atomic structure of ROC GTPase. (A) Stereoview of the domain-swapped
dimer. The two individual monomers are shown in yellow and green. (B) Ribbon rep-
resentation of a single monomer. The three head, neck, and body subdomains are
indicated, along with the labeled secondary structures. The P-loop, G3/Switch II,
and G4 and G5 loops are indicated in orange, pink, red, and cyan, respectively. The
disordered G2 loop is shown as a black dotted curve. (C) Surface representation high-
lighting the GDP-Mg2+ binding pocket on the surface of the dimer that is contributed
from both monomers. The pair of functional units are shown as ROCs1 and ROCs2,
respectively. (Deng et al., 2008)
Until now, only the crystal structure that has been solved is that of the human LRRK2
Roc GTPase domain. The Roc domain displays a dimeric structure where the dimeric
fold forms an extensive domain swapping at the catalytic core. Each of the Roc domain
monomer contains five α-helices and six β-strands. There are other sub domains as well,
which forms the head, neck and body and a pair of active sites. The two monomers
are arranged in a pseudo two-fold symmetry and are further stabilized by hydrophobic
interactions and extensive hydrogen bonding(Deng et al. 2008). Three of the LRRK2
pathogenic mutations lie within the Roc domain at residue R1441 (R1441C, R1441G,
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and R1441H). The residue R1441 is located at the end of α-helix 3 that is further linked
with the carbonyl oxygen of F1401 residue and the hydroxyl group of T1404 residue,
which are located on α-helix 2 from the other peptide chain at the dimer interface
via hydrogen bonding. The R1441C mutation is believed to weaken the Roc dimer
structure by disrupting the hydrogen bonding thereby destabilizing the dimer formation
(Figure 2.7)(Deng et al. 2008). The importance of dimeric formation of the Roc domain
and its affect on Roc GTPase activity has been further confirmed by other studies(Guo
et al. 2007; Ito et al. 2007). Another putative mutation PD linked mutation I1371V
lies near the conserved GTP binding pocket and can alter the catalytic activity of the
domain.
Figure 2.8: Structure of the Roc-COR tandem. (A) Stereo-ribbon diagram of the
Roc-COR dimer with COR domains A and B, and for Roc domain A and parts of Roc
domain B in different shades of blue. (B) Ribbon plot of Roc domain A and helix 0
(E) Schematic view of the complete Roc-COR dimer including the full Roc-B subunit.
(Gotthardt et al., 2008)
Another study aimed to gain insight into the human LRRK2 Roc-COR domain by solv-
ing the structure of its prokaryotic homologue in C. tepidum(Gotthardt et al. 2008).
Roc-COR domain of the homologous ROCO protein in C. tepidum was isolated from
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the full-length protein by limited proteolysis method and subject to cystalization and
structure determination by X-ray crystallography (Figure 2.8). The COR domain is com-
prised of two subdomains which are linked by a flexible linker domain. Each subdomain
is further made up of mostly α-helical structure with a short N-terminal β-sheet which
is antiparallel and have three short strands. Towards the C-terminal, there is a cen-
tral seven-stranded antiparallel β-sheet flanked by four α-helices and a β-hairpin motif.
The two subdomains of the COR forms a dimeric structure (Figure 2.8). The structure
has confirmed that the dimerization in the Roc-COR tandem structures occurs at the
C-terminal of COR subdomains. The interactions between Roc and the COR domains
contributes to the dimer formation. It was reported in the study that the PD linked
mutation occur between the Roc and COR domains and involve the α-helix 3 of Roc
domain which causes the disruption of the hydrogen bonding and reduce the interaction
between Roc-COR tandem and therefore decreasing the GTPase activity(Gotthardt et
al. 2008). This study identified the dimerization of Roc-COR to be mediated by the
COR domain which contradicts the previous claims from the crystal structure of the Roc
dimer, and suggested a Roc mediated dimerization(Deng et al. 2008). These ambiguities
further emphasize the need of a full-length structure of LRRK2 at high resolution.
Figure 2.9: Structural of the COR domain dimer. (A) Ribbon diagram of one (physi-
ological dimer) of the COR dimers found in the crystal, with different protomers shown
in green and cyan. Loops, that are not visible in the structure are indicated as dashed
lines. (B) Surface representation of the COR monomer in two different orientations
separated by 180◦, with residues totally invariant between bacteria and man in red and
those highly conserved in orange. (Gotthardt et al., 2008)
2.2.2.4 C-terminal of Roc (COR) domain
Another characteristic domain common to all the ROCO proteins is the COR domain.
It always occurs immediately after the Roc Domain. This tandem arrangement of Roc-
COR is highly conserved in all organisms and throughout evolution, which suggests
the mutual dependence of function between the two main domains of ROCO proteins.
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The COR domain comprises of 300-400 residues (Figure 2.9). There have been several
bioinformatics studies to understand the sequence homology of the domains but COR
domain does not show any significant homology to any known protein domain.
2.2.2.5 Kinase domain
The kinase domain in LRRK2 is also called mitogen-activated protein kinase kinase ki-
nase (MAPKKK) domain. Based on the sequence similarity, the kinase domain of the
LRRK2 belongs to the tyrosine kinase-like (TKL) subfamily of human protein kinases.
The members of TKL protein kinase family show sequence similarity to both tyrosine
kinases as well as serine/threonine kinases(Manning et al. 2002). The kinase domain
also bears resemblance to the receptor interacting protein kinases (RIPKs), a class of
protein kinases important in sensing cellular stress and activate mitogen-activated pro-
tein kinase (MAPK) pathways(Meylan and Tschopp 2005). The atomic structure of the
kinase domain of LRRK2 has not yet been solved. By utilising the close homology with
human B-Raf for which the atomic structure is already known by X-ray crystallography
(Figure 2.10, A), a homology model can be generated for LRRK2 kinase domain. The
kinase motif DF/YG that is conserved motif of kinase lies at the interface of the small
and the large catalytic lobes. The motif responsible for magnesium ion binding is called
the D motif. Magnesium ion binding is required for the ATP phosphotransfer(Guo et
al. 2006). For the interaction with the alpha carbon helix via hydrophilic interactions,
rest of the motif is responsible and this is found to be critical for the catalytic activ-
ity(Nolen et al. 2004). For the activity of the protein kinases, majority of them requires
phosphorylations of the activation segment. Once phosphorylated, the activation seg-
ment undergoes a conformational change, thereby enabling binding of the substrate and
required catalysis can be performed. The PD-associated LRRK2 mutations G2019S
and I2020T are placed at the N terminal end of the activation segment, with glycine
residue position 2019, which belongs to the conserved DF/YF sequence. Another PD
related mutation of LRRK2 I2012T lies within the magnesium binding region of the
domain(Mata et al. 2006). These mutations therefore directly affect the kinase catalytic
activity.
Recently, a high-resolution structure of the ameba LRRK2 kinase domain homolog has
been solved with X-ray crystallography and proposed as a platform for understanding
the human LRRK2 kinase domain (Gilsbach et al. 2012). The kinase domain was
purified and crystallized from ROCO4, the Roco family protein in Dictyostelium. Roco4
has the same domain architecture as LRRK2 and much more stable biochemically and
structurally. The 3D structure of Roco4 kinase is very similar to that of other kinases.
It is comprised of two-lobed kinase structure, with an adenine nucleotide bound in the
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Figure 2.10: Atomic models of Kinase domain. (A) PDB model of B-Raf, a known
MAPKKK activated by Ras (pdb no. 1UWH). (B) Crystal Structure of the Roco4
Kinase Domain bound to AppCp from D. discoideum (PDB No. 4F0F) (C) Homology
model of human LRRK2 Kinase domain, using Discoideum Roco4 Kinase Domain as a
template (Cardona et al., 2014)
conventional nucleotide-binding pocket (Figure 2.10, B). The N-terminal lobe is slightly
smaller and is mostly comprised of anti-parallel β sheets. It also contains the conserved
αC-helix. The other C-terminal lobe is relatively bigger and composed of α-helices
and contains the activation loop with the conserved N-terminal DFG motif. The cleft
between the two lobes forms the ATP binding site and acts as the catalytic core of
the kinase together with αC-helix and the activation loop. The atomic structure also
revealed for the correct position of the αC-helix, a polar contact formation is essential
between Roco4 Lys 1055 from the β3-strand and Glu1078 from the αC-helix. While
for the catalysis, the DFG motif is essential. The Asp residue makes contact with all
three ATP phosphates either directly or via coordination of a magnesium ion; the Phe
residue makes hydrophobic contacts to the αC-helix and the HxD motif is responsible
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for the correct positioning of the DFG motif. Using the atomic model of Roco4 as a
template, Cardona and colleagues generated a model for human LRRK2 Kinase domain
using homology modelling. The domain is formed by seven α-helices and six β-sheets
linked by loops, which are exposed to the solvent (Figure 2.10, C) (Cardona et al. 2014).
2.2.2.6 WD40 domain
There are seven repeats of WD40 in LRRK2. The typical architecture of WD repeat
comprises of the N-terminal GG dipeptides of 11-24 residues and the C-terminal WD
dipeptide ranging from 40-60 residues. Sandwiched between the C and N terminal is
a conserved sequence that forms the core of this domain. Each repeat forms a four-
stranded, antiparallel beta pleated sheets and forms a circular propeller-like structure
(Figure 2.11)(Mata et al. 2006). Despite the highly conserved motif and sequence
similarity between the proteins that contain the WD40 domain, they all posses a high
diversity in their function. This is very unusual for a domain where the expected tertiary
structure is very similar. There are a number of WD40 containing proteins in eukaryotes
and carry out diverse functions like RNA processing, cytoskeleton assembly, cellular
trafficking and transcription regulation. In most of these cellular processes, the WD40
domain does not perform any enzymatic function but rather mainly functions to mediate
protein-protein interactions. There are special proteins like LRRK2, where WD40 is
fused with the kinase domain in the C-terminal(Janda et al. 1996; Smith et al. 1999).
In relation to Parkinson’s disease there has been two putative pathogenic mutations in
LRRK2 WD40 domain. The first mutation, G2385R is located on the surface of one of
the propeller blade and postulated to be involved in altering protein-protein interaction.
While the second mutation, T2358I is located in the core part of the domain(Mata et
al. 2006).
Figure 2.11: A model resembling the predicted repeat pattern of the LRRK2 WD-40
repeat domain. (Mills et al., 2014)
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2.2.3 Prevalence of LRRK2 mutations in Parkinson’s disease
Mutations in the LRRK2 and their link with Parkinson disease have brought widespread
public attention to the pathobiology of LRRK2 in PD. In comparison to other genes
which are involved in PD, LRRK2 linked PD has two special aspects. Firstly, mutations
in LRRK2 gene is found not only in familial form of the disease but for sporadic cases as
well and secondly, pathobiological features of the LRRK2 linked PD, both for familial
and sporadic cases, are very similar to each other(Bonifati 2006). Of all the known mu-
tations for LRRK2, the G2019S mutation, located in the kinase domain of the protein is
the most commonly occurring in both familial and sporadic PD. The G2019S mutation
is found in 1-2% of sporadic PD patients while 3-6% of patients with familial PD are
known to have this mutation. Although several groups have identified this mutation
and linked it with PD, the frequency of the G2019S mutation varies greatly with the
geographic population. For example in Europe, the G2019S mutation is present at a
comparatively lower frequency 4-18% of familial PD and 1-6% of sporadic PD, with
slightly more prevalence in southern European countries than the northern European
countries. In contrast the prevalence of G2019S mutation is extremely low in Asian
population(Lu et al. 2005; Tan et al. 2005; Fung, Chen, Hardy, Hernandez, et al. 2006;
Punia et al. 2006; Tomiyama et al. 2006). However, among patients from the middle
east, Arab states, North Africa and Jewish population, extremely high prevalence is
observed (30-38% of familial and 15-22% of sporadic cases)(Lesage et al. 2006). The
penetration of G2019S mutations in PD patients appears to be dependent on age, in-
creasing from around 20% at the age of 50 to as high as 85% when the patient reaches
70(Kachergus et al. 2005). In recent studies, the lifetime penetration of G2019S mu-
tation in large scale studies in PD patients population from United States and Europe
yielded figures between 24 to 33%, this explains the high occurrence of G2019S mutation
in sporadic PD case(Goldwurm et al. 2007; Clark et al. 2006). Apart from G2019S,
there are other mutations in LRRK2 that are linked to PD in many studies, though
the prevalence is generally lower than that of G2019S. Among these other mutations,
another common PD related mutation located in the Roc domain are the R1441G and
R1441C mutations. The R1441G mutation has been associated with among Spanish and
Basque PD patients with a very high prevalence of around 8%.(Paisan-Ruiz et al. 2004).
For the other common mutation, R1441C, a prevalence of 3.4 % was reported in a study
on 60 European families(Di Fonzo, Wu-Chou, et al. 2006). Apart from the catalytic
core of Roc-COR and Kinase domains, another G2385R variant, located in the WD40
domain, has been identified as a common risk factor for sporadic PD in populations of
Chinese ethnicity(Di Fonzo, Tassorelli, et al. 2006; Fung, Chen, Hardy, Singleton, et al.
2006; Tan et al. 2007). Other putative mutations, located all along the multi-domain
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structure of LRRK2 are known but have been have been reported with a rather low fre-
quency of ¡ 1%(Punia et al. 2006). These include S1228T, R1441H, R1067Q, I1122V,,
Y1699C, I2020T and M1869T.
2.2.4 Localization of LRRK2
Studies of mRNA expression pattern in mouse showed that expression pattern of LRRK2
differ significantly from the other PD related genes. For example, mRNA expression lev-
els of other PD related genes like α-synuclein, parkin, UCHL-1, DJ-1, and PINK1 are
observed in most of the neurons of the brain including the dopamine neurons located
in the midbrain(Galter et al. 2007; Solano et al. 2000). In contrary, LRRK2 mRNA
expression is absent in dopamine synthesising neurons of the SNpc and only observed
in dopaminergic areas of the brain such as the striatum, olfactory tubercle and cor-
tex(Melrose et al. 2006; Galter et al. 2006; Taymans et al. 2006).
Apart from the brain, LRRK2 is expressed broadly in peripheral organs like liver, lungs,
kidneys and spleen(Higashi et al. 2007). Intracellularly, LRRK2 has found to be local-
ized within a number of cellular organelles like Golgi vesicles, plasma membrane, lyso-
somes, mitochondria, synaptic vesicles and cytoskeleton. These localizations of LRRK2
hints towards a putative role in cellular vesicle trafficking, mitochondrial integrity and
protein turnover. There is also substantially higher expression of LRRK2 in the immune
system than in the brain cells which implies the emerging role of LRRK2 in the immune
regulation(Dzamko and Halliday 2012). Recently, a study has suggested that in ad-
ditional to the cytosolic monomer LRRK2, membrane associated LRRK2 can exists as
dimeric structure and possesses enhanced kinase activity and GTPase activity compared
to the soluble counterparts(Sen et al. 2009).
In brain cells of humans, both the LRRK2 mRNA and LRRK2 protein expression are
found in the regions of brain like cerebral cortex, SNpc and caudate putamen, which
are pathologically relevant in PD(Biskup et al. 2006). There are also studies to support
the co-localization of LRRK2 with α-synuclein in the brainstems and lewy bodies(Zhu,
Babar, et al. 2006; Zhu, Siedlak, et al. 2006). There has been conflicting evidence
regarding the immunostaining of Lewy bodies for LRRK2, when other groups failed to
detect any LRRK2 protein in Lewy bodies(Greggio et al. 2006). This reported am-
biguity might be a result of utilization of diverse LRRK2 antibodies or variations in
preparation of brain tissues for immunohistochemistry.
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2.2.5 LRRK2 and Mitochondrial dysfunction
Over the past few years, mitochondrial dysfunction has been increasingly appreciated
as a key modulator in neurodegenerative diseases and now recognised as a key feature
of both sporadic as well as familial Parkinsonism. Mitochondria are vital organelles of
the cell, which are responsible for cellular ATP synthesis, calcium homeostasis, apopto-
sis initiation and ROS formation. An important aspect of mitochondrial functioning is
the fission and fusion dynamics they go through and this key fission-fusion mitochon-
drial dynamics is essential for integrity, electrical balance and protection of mitochon-
dria(Berman et al. 2008). Moreover, the critical role of cellular respiration in the brain
functioning and its impairment has been implicated in PD and several other neurodegen-
erative diseases. The implication of mitochondrial autophagy in PD linked with LRRK2
came from the study of mutant mouse carrying the human G2019S mutant LRRK2
and it was observed that there was aggregation and accumulation of mitochondria in
the brain(Ramonet et al. 2011). In another study, a major reduction in the levels of
ATP and altered morphology of mitochondria was identified in fibroblast with the same
G2019S LRRK2 mutation of PD patients(Mortiboys et al. 2010). It was later validated
that wild type LRRK2 interacts with a number of mitochondrial fission fusion regulators
by co-localizing with the regulators in the cytosol as well as the membranes, indicating
for the first time a directly regulatory role(Wang et al. 2012; Stafa et al. 2014). Together
in the primary neurons of rats and the human neuroblastoma, it has been established
that LRRK2 directly interacts with Drp1, the key fission regulator of the mitochon-
dria at the membrane which further activates Drp1 by phosphorylation and increase
mitochondrial fission(Niu et al. 2012; Stafa et al. 2014). This fission mechanism of mi-
tochondria via the LRRK2-Drp1 mediated pathway is enhanced by overexpression wild
type LRRK2 as well as G2019S mutant LRRK2, however, the process can be rescued by
the inhibition of Drp1 or fusion enhancement (Figure 2.12)(Su & Qi 2013). LRRK2 also
have been reported to interact with two other key mitochondrial fusion regulators Mfn
1/2 and OPA1 and modulates their activity, as the PD patients carrying the common
G2019S mutation showed reduced level of mature OPA1(Stafa et al. 2014). Studies
on the LRRK2 orthologue LRK-1 in C. elegans also revealed protective role of LRK-1
in mitochondrial stress by acting antagonistically with PINK-1(Samann et al. 2009).
All together, these data demonstrate a close interaction between the mitochondria and
LRRK2 but till date, it has been impossible to confirm mitochondrial dysfunction as
the primary pathogenic effect of LRRK2 linked PD.
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Figure 2.12: Overview of the roles of LRRK2 in mitochondrial dysfunction : LRRK2
activates the mitochondrial fission protein dynamin related protein-1 (Drp1) via phos-
phorylation. Increase in the kinase activity can results in aberrant Drp1 phosphoryla-
tion and fission. In G2019S mutated PD associated LRRK2, increased fission and ROS
production leads to mitochondrial dysfunction. The increased number of fragmented
mitochondria will increase autophagic flux due to the increase in mitophagic cargo.
LRRK2 mutations can impair CMA resulting in cellular stress.(Adapted from Ryan et
al., 2015)
2.2.6 Enzymatic activity of LRRK2
The catalytic core of LRRK2 that comprises of the Roc-COR domain and the kinase
domain has been studied well in the past few years. LRRK2 functions both as a func-
tional GTPase as well as a kinase which can undergo autophosphorylation and substrate
phosphorylation(Gloeckner et al. 2006; West et al. 2005).
LRRK2 is identified as a GTP-binding protein as confirmed by the studies using ra-
diolabeled GTP and GTP-agarose(Lewis et al. 2007; Guo et al. 2007). LRRK2 have
been shown to have the ability to bind and hydrolyze GTP(Li et al. 2007). Biochemical
studies carried out to understand the kinase activity routinely measure the autophos-
phorylation of LRRK2 itself or phosphorylation of Myelin Basic Protein (MBP) as a
generic kinase substrate and phosphorylation of an artificial substrate called LRRK-
tide(Lewis 2012). Though the status of these proteins as substrates for LRRK2 remains
unclear. The most prevalent mutation of LRRK2 G2019S has been found to directly
affect the kinase activity and increase it to as much as threefold when compared to the
kinase activity in WT LRRK2. As the mutation is located in the catalytic core of the
kinase domain, it can likely affect the conformation of the kinase domain and affects its
enzymatic action(Smith et al. 2006; Guo et al. 2007; Ito et al. 2007; West et al. 2007).
Another common mutation R1441C that occur in the Roc domain has been reported
in several studies to decrease the GTPase activity and the GTP turnover rate, without
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affecting the GTP binding of the protein (Gloeckner et al. 2006; West et al. 2005; Li et
al. 2007).
Other familial PD linked mutations like R1441C, R1441G, I1371V and Y1699C located
within the Roc and COR domains are shown to cause increased GTP-binding as mea-
sured by binding to GTP-agarose, while mutations outside these domains did not affect
GTP-binding compared to wild-type LRRK2(West et al. 2007). In contrast, R1441C
mutation also have been demonstrated to enhance GTP binding in LRRK2 with mu-
tation as compared to the wild type in other studies(Lewis et al. 2007; Guo et al.
2007).
There are two types of autophosphorylation that can occur, within the same molecule,
which is termed as intramolecular phosphorylation or with other molecules, which is
called intermolecular phosphorylation. Luzon and colleagues demonstrated that LRRK2
expressed in bacteria displays intermolecular autophosphorylation targeting T2031 and
S2032 residues in the activation segment(Luzon-Toro et al. 2007). There have been
other autophosphorylation sites that have been recognised which include those located
in the Roc domain like S1403, T1404, T1410, T1491 as well as those located in the
kinase domain T1967 and T1969. The kinase domain is shown to influence the GTPase
domain as well as other domains(Kamikawaji et al. 2009). This hypothesis has been
tested in another study which reported that GTPase activity can be modified by the
auto-phosphorylation of the LRRK2 T1503 site located in the GTPase domain(Webber
et al. 2011), which further supports the idea that the kinase domain may influence the
GTPase domain in LRRK2.
The enzymatic activity of LRRK2 has been demonstrated to be strongly correlated
with its dimerization. The most common pathological G2019S mutation in LRRK2
enhances dimerization of the protein and results in enhanced kinase activity. Using
kinase inhibitors results in disruption of LRRK2 dimers and higher weight oligomer
formation is promoted(Sen et al. 2009).
Several studies have reported the kinase activity of MAPKKK domain of the LRRK2
and the effect of PD related mutations on its enzymatic activity. The G2019S mutation
is considered to enhance the kinase activity in LRRK2 in vitro and therefore LRRK2
linked PD is characterised as gain-of-function of protein kinase activity. Mutants of
LRRK2 with inactive kinase activity are found to be less toxic both in vitro and in
vivo(Greggio et al. 2006; Smith et al. 2006; Zhihua Liu et al. 2011; S. Lee et al. 2010).
But there still exists some discrepancies in the literature and there is no clear consen-
sus regarding the affect PD associated mutation has on the kinase activity of LRRK2.
For example, there are studies where other common mutations like R1441C, R1441G,
R1514Q, Y1699C and I2020T are reported to enhance the kinase activity measured by
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autophosphorylation, confirming the gain-of-function mechanism model for the LRRK2-
linked PD, in contrast there are other studies that report these mutants either do not
influence any kinase activity or even inhibit the kinase activity(Jaleel et al. 2007; Luzn-
Toro et al. 2007). According to one in vivo study, it was reported that the inhibition of
kinase activity in LRRK2 can also decrease the LRRK2 protein level in mouse kidney
and lung, implying that LRRK2 kinase activity may be able to control the protein level
as well(Herzig et al. 2011). Another interesting aspect of the kinase activity in LRRK2
is its ability to affect its protein-protein interaction and also cellular localization. The
phosphorylation of S910/935 is necessary for the interaction of LRRK2 with other 14-3-3
proteins, confirmed by mutant studies of S910/935 LRRK2, which started to accumulate
in the cytoplasm(Nichols et al. 2010; Dzamko et al. 2010).
2.2.7 LRRK2 therapeutic strategy
For the development of therapeutics for LRRK2 related PD, a great understanding of
the biological functioning and cellular signaling is very important. The role of LRRK2
to function as a kinase has been well established, which makes it an interesting clinical
target. Therefore a specific inhibitor against the kinase core of the protein can be
a potential treatment regime in PD. Converging studies directs to the inhibition of
LRRK2 kinase activity as a key therapeutic concept and there has been recently a lot
of research in this particular area. Several generic kinase inhibitors has been studied
against LRRK2 and found to inhibit LRRK2 kinase activity and protect against LRRK2
toxicity both in vitro and in vivo(B. D. Lee et al. 2010). Other kinase inhibitors like
GW5074 and sorafenib were also reported to protect against G2019S LRRK2-induced
neurodegeneration(Zhaohui Liu et al. 2011). The effect of LRRK2 kinase inhibition
can also cause cellular changes for example, LRRK2 kinase inhibitors were found to
dephosphorylate LRRK2 at S910/935 mutation, and further restrict the interaction with
14-3-3 and promote formation of inclusion bodies(Dzamko et al. 2010). There is still
information lacking to explains the cellular correlations of the protective effect induced
by LRRK2 inhibitors. But nonetheless several potent, promising kinase inhibitors are
discovered. One such inhibitor is LRRK2-IN1, which unfortunately could not get clinical
approval because of the inability to cross the blood brain barrier. The IC50 value
of LRRK2-IN1 is 6 mM for G2019S and 13mM for WT LRRK2(Deng et al. 2011).
Though kinase inhibitors has proved to be a promising therapeutic drug for LRRK2,
there has been some concern on their usage. It has been reported in a study that
inhibition of LRRK2 kinase activity can also lead to decrease in LRRK2 protein level in
cells and disrupt normal kidney function and lung homeostasis, which can cause organ
malfunction(Herzig et al. 2011). To counteract such side effect of kinase inhibitors, more
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research on strategies to directly target the inhibitors to the brain might be needed in
future.
2.3 LRRK1
Apart from LRRK2, there are three other ROCO family proteins that have been iden-
tified in humans. These are Leucine-rich repeat kinase 1 (LRRK1), death-associated
kinase 1 (DAPK1) and Malignant fibrous histiocytoma amplified sequence 1 (MFASHI1)
(Bosgraaf and Van Haastert 2003). Of these the closest paralogue of LRRK2 is LRRK1.
Both the LRRKs shared a conserved domain architecture that is typical of the ROCO
family of proteins. LRRK1 is a 2015 amino acids long protein and structurally lacks
the ARM and WD40 domains of LRRK2(Taylor et al. 2007; Korr et al. 2006). Apart
form the missing domains, the sequence identity and similarity between the common
domains of the two proteins varies between 14% and 50% (Figure 2.13)(Civiero et al.
2012). Moreover, both proteins are basally phosphorylated(Greggio et al. 2007) and
expressed in the brain(Biskup et al. 2007). However, irrespective of their similar ex-
pression profile and close homology, mutations in LRRK1 have not been genetically
associated with PD(Taylor et al. 2007). Although in a recent exome sequencing in a
German family with autosomal dominant late-onset PD, LRRK1 along with EEF1D
were identified as the best candidate, hinting at a possible role of LRRK1 in addition
to LRRK2 in the genetic foundation of PD(Schulte et al. 2014). But more conclusive
studies are required to find LRRK1 variants as causative agents of PD. A study induced
PD linked mutations in both LRRK2 and LRRK1 at equivalent residues to determine
the comparative toxicity level and it was found that mutations in LRRK1 is much less
prone to form inclusion bodies in transfected cells, thereby suggesting that LRRK2 is
inherently more pathologically toxic than LRRK1(Greggio et al. 2007). This major dif-
ference has invoked various other studies to understand the functional roles of LRRK2
and LRRK1 and the link between the two (Taylor et al. 2007). Importantly, LRRK1
might have a modulatory role in the signaling network of LRRK2 and, therefore, affect
the risk of developing PD (Dachsel et al. 2010; Klein et al. 2009; Reyniers et al. 2014).
Unfortunately, the limited amount of structural information available for LRRK1 and
LRRK2 does not allow definite conclusions to be drawn.
2.3.1 Biochemistry
The biochemical properties of LRRK1 have not been explored well and there are only
a few reports published in literature that describe its function as a GTPase or a ki-
nase. Among the first biochemical study carried on LRRK1 was published by Korr and
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Figure 2.13: Domain organisation of LRRK1. Predicted domains (Mills et al. 2014)
are depicted with different colors and their relative location is drawn to scale within
the full-length protein : ANK, ankyrin repeats; LRR, leucine-rich repeats; ROC, Ras
Of Complex proteins GTPase; COR, C-terminal Of ROC; KIN, a kinase. Below each
domain, the sequence identity and sequence similarity with domains of LRRK2 is re-
ported in the column with same color. (Bioinformatics values adapted from Civiero et
al., 2012)
colleagues, a decade ago where they proposed that like LRRK2, LRRK1 also function
as a GDP/GTP binding protein via the ROC domain and undergoes autophosphoryla-
tion(Korr et al. 2006). In the same study, the kinase activity of LRRK1 was measured
by saturating the GTP-binding site, which resulted in loss of kinase activity, suggesting
the dependence of kinase activity in LRRK1 on the GTPase domain. The efficiency of
the catalytic activity of LRRK1 was found to be lower than that of LRRK2(Deng et al.
2011; Bosgraaf and Van Haastert 2003). One key difficulty in studying the biochemistry
of LRRK1 and LRRK2 is the lack to known substrate for the kinase and GTPase activ-
ity. To make things difficult, the commonly used kinase substrate that are routinely used
to study other kinases in cells such as MBP (myelin basic protein), casein and histone
H1 are not phosphorylated by LRRK1(Korr et al. 2006). Furthermore, till date the
published reports on the studies to investigate the biological functions of LRRK1 have
been on truncated recombinant form of LRRK2 or attached with affinity tags. There
has been lack of efficient purification methodology that can yield good quality full-length
functional LRRK1 protein, which can be used to unravel the molecular mechanism of
LRRK1 functional activity.
2.3.2 Functions
Although both LRRK2 and LRRK1 display similar function and display partial intra-
cellular co-localization, when the well-known PD associated LRRK2 mutations were
introduced into LRRK1, it resulted into different phenotype. It was found that the au-
tophosphorylation activity as well as the propensity of LRRK1 to induce cell death was
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not affected by the LRRK2 PD associated mutation, as observed for mutated LRRK2
protein(Korr et al. 2006; Greggio et al. 2007). It has been reported that LRRK2 is
predominantly a functional dimer in the cell and the kinase activity is modulated by
the dimeric nature of LRRK2(Deng et al. 2008; Greggio et al. 2008; Berger et al. 2010;
Sen et al. 2009). However, there are also report of LRRK2 to be present in cell in
monomeric form which is probably inactive(Ito and Iwatsubo 2012). Based on these
findings and the fact that there is high level of homology and similarity in domain or-
ganization between the LRRK2 and LRRK1, it is conceivable to deduce that LRRK1
too has very similar quaternary-structural properties as that of LRRK2. A study con-
firmed the hypothesis that dimerization is a general attribute of the ROCO family of
proteins including LRRK1, LRRK2 and DAPK1(Klein et al. 2009). Another interesting
study also revealed the occurrence of formation of heterodimers between LRRK1 and
LRRK2(Dachsel et al. 2010). This phenomenon is also seen in other class of proteins
called GAD, which stands for G-proteins activated, by nucleotide-dependent dimeriza-
tion. GAD undergo pseudo trans homodimerization whereby two different G-protein
that share similar family and near identical active side residues can form dimers(Gasper
et al. 2009). Similarly, LRRK1-LRRK2 heterodimerization could have an affect on the
kinase activity and maintaining the equilibrium between the dimer and other oligomeric
states. But there is further need to establish the role of LRRK1 as modulator of LRRK2
3D structure and also the affect of pathogenic PD mutations on heterodimerization.
There have been few studies that demonstrated the role of LRRK1 in endocytosis of
EGFR (epidermal growth factor receptor). It was shown that LRRK1 forms a sta-
ble complex with activated EGFR by forming and interacting with another protein
Grb2 (growth-factor-receptor-bound protein 2)(Hanafusa et al. 2011). LRRK1 is also
reported to regulate endosomal trafficking in cells. EGFR regulates LRRK1 kinase ac-
tivity through Try944 phosphorylation(Ishikawa et al. 2012). When Tyr944 residue of
LRRK1 was mutated (Y944F), EGF stimulated tyrosine phosphorylation was halted.
This resulted in gain of function for LRRK1 kinase activity and increased mobility of
endosomes towards particular region. The same group of researchers also found that
LRRK1 interact with NudC and CLIP-170 (cytoplasmic linker protein 170), linking the
role of LRRK1 to endocytosis(Hanafusa et al. 2011). Recently, CLIP-170, a microtubule
plus-end protein, has been identified as downstream targets of LRRK1. This further pro-
motes the association of CLIP-170 with dynein-dynactin complexes, hence providing a
new biological function of LRRK1 in the dynein-driven transport of EGFR(Kedashiro et
al. 2015). These observations when compared with the known functions of LRRK2, im-
plies that LRRK1 and LRRK2 may share cellular functions. The association of LRRK2
with PD and no clear involvement of LRRK1 in PD has lead to a far wider research into
exploring the cellular function of LRRK2, while for LRRK1, a lots of inspection is still
needed.
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2.3.3 Localization of LRRK1
To localize LRRK1 in cells, the common strategy used in the studies is to measure the
LRRK1 mRNA and protein level in different tissues and organs, together with LRRK2,
the data are suggestive that the expression of the LRRK1 and LRRK2 usually overlaps
and in few organs such as the kidneys and the brain, level of LRRK2 mRNA expression
is much higher than that of LRRK1(Dachsel et al. 2010; Biskup et al. 2007). In tissues
like these where the expression of LRRK1 is lower, the functional overlap of LRRK1
and LRRK2 is nullified because of the low quantity of one protein but in other organs
where the expression of both LRRK1 and LRRK2 is similar, the functional overlap can
compensate for the deficiency of one protein. In a recent study, detailed analysis of
LRRK1 and LRRK2 was carried out using radioactive in situ hybridization to explore
the localization, expression level and distribution of the proteins. The expression pro-
files of both genes at low level from embryonic stage E9.5 onward, which progressively
increased up until birth, showed that there are no prominent LRRK2 mRNA signals
at these time-points. Although, after the birth, the level of LRRK2 in the brain espe-
cially in the striatum and the cortex of adult mice is very strong, while LRRK1 levels
were comparatively very low and only detectable in mitral cell layer of the olfactory
bulb(Giesert et al. 2013). Therefore a redundant function of LRRK1 and LRRK2 in
the pathogenesis of PD seems unlikely as observed in the non-overlapping expression
patterns in the mouse brain.
2.3.4 LRRK1 and LRRK2
Although, LRRK1 and LRRK2 both share a common evolutionary ancestry, they are
both specialized for different functions. The catalytic core of the LRRKs i.e. the ROC-
Cor-Kinase domain imparts similar molecular mechanism to perform these different
task but the higher degree of variation in the repeating domains (ARM, ANK, LRR,
WD40) which are crucial for the protein-protein interactions may play an important
role in regulating the binding partner and target their cellular functions. Therefore, for
a better understanding of the functions and dysfunctions of LRRKs, there is a need to
study the actions of LRRK2 and LRRK1 in parallel in different animal models(Civiero
and Bubacco 2012). There has been a study to understand LRRK1 and LRRK2 specific
cellular processes by identifying their interacting partner. Using protein microarray-
based interaction screen, coimmunoprecipitation and followed by mass spectrometry,
specific as well as common interacting proteins were identified for both LRRK1 and
LRRK2 in parallel (Reyniers et al. 2014). The study confirms both the protein can
carry out distinct functions by interacting with different cellular partners, suggesting
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that the LRRK1 signalling does not intersect with LRRK2 signalling, thereby reflecting
a different role of both LRRKs in pathogenicity of PD.
2.4 Electron microscopy
2.4.1 Introduction and History
The invention of microscopes has been from long one of the most fascinating events in
understanding the secrets of living forms. The resolution of human eye is in the order
of 100 um which makes anything smaller than the thickness of human hair unseenable
to the human eyes. In the past centuries, light microscopy has pushed this resolution
limitation and has been instrumental in many of the important discoveries in biology
and medicine. However, at the end of nineteenth century the resolution limit of a
conventional light microscope reached its limit, which is approximately 250 nanometers
equal to the wavelength of the incoming light used to illuminate the sample. In 1930s,
Ernst Ruska and Max Knoll came up with a prototype of a new kind of microscope that
uses an illumination source with a smaller wavelength need and this source was high
voltage electrons and gave birth to the Electron Microscope (EM) (Borries and Ruska,
1938). This enabled scientist to view the structures inside the cells well below the reach
of light microscope and opened an entire new field in biology.
There are two common types of electron microscopes: scanning electron microscope
(SEM) and transmission electron microscope (TEM). In a typical SEM, biological sam-
ple of interest is first coated with a electron reflecting metal. This metal layer also acts
as a conducting surface and protects the sample from charging, when the electron beam
from the microscope scans over the biological sample. The resulting image formed by
the bouncing electrons off the surface reveals a 3D picture of the specimen without any
internal information. In contrast, a TEM produces an image that is a 2D projection
of the biological object, including not only the surface but also the internal structure.
When the beam of electrons from the microscope, interacts with the sample, it passes
through the entire thickness of the sample, hence enabling to differentiate the internal
structures based on the different projections obtained. These different projects of the
same biological entity from different directions or views can then be computationally
combined to deduce a 3D reconstruction. But before the technique could be used as a
general structural biology method, three key challenges needed to be overcome. First,
the biological sample has to sustain the ultra high vacuum that is required for the func-
tioning of the TEM. Secondly, a workaround to decrease the radiation damage to the
sample caused by the high-energy electron beam. And lastly, the contrast generated
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from the biological sample is very low. It was David DeRosier and Aaron Klug who
for the first time in late 1960s tackled these problems by using the heavy-atoms salts
as staining chemicals. They used computational Fourier-Bessel approaches to mathe-
matically combine the multiple projections of T4 bacteriophage tail, which compose of
molecules arranged in a helical order (De Rosier & Klug, 1968). This gave birth to the
field of 3DEM. Though the use of heavy-metal staining in EM called negative staining
is still a popular method, which generates high-contrast image and protects the sample
from the radiation damage, there are some major limitations to this method, the staining
and drying of the sample can cause the sample to collapse and most importantly limit
the resolution to get a detailed biological insight of the sample. The major breakthrough
for high resolution EM came from the work of Ken Taylor and Robert Glaeser (Taylor
& Glaeser, 1974). They demonstrated that high-resolution features of a protein can
be protected by keeping the sample frozen hydrated at cryogenic temperatures. Their
work shifted the field of EM into cryo-EM. Later Dubochet and colleagues developed the
method of vitrification of samples for cryo-EM which is still routinely used (Dubochet
et al., 1988). During the year of development of the cryo-EM field, several pioneering
work bought high-resolution atomic models of biological samples. These include the
structure of bacteriorhodopsin (Henderson et al., 1990), acetylcholine receptor (Unwin,
1995) and Icosahedral viruses (Bttcher, Wynne, & Crowther, 1997; Conway et al., 1997).
All these samples either formed naturally occurring 2D crystals or have had some form
of symmetry that limited the use of 3DEM to a group of biological specific following in
those categories. Methodology to deal individual macromolecular complexes in cell that
doesnt form helical or crystalline arrays and adopt random multiple orientation when
vitrified in a EM grid, came from the study of ribosomes by Frank and colleagues (M.
J. Frank, 2005). Their work broaden the horizon of cryo-EM field and enable many
more biological complexes to be structurally determined by the so called single particle
reconstruction.
2.4.2 The Electron Microscope
The basic layout and working of a transmission electron microscope is in a way very
similar to that of a conventional compound optical microscope (Figure 2.14). At the top
of the TEM, a high voltage electron source is placed, which generates very high voltage
electron beam, which travels down the column passing through the sample and a series
of magnifying magnetic lenses. The column chamber is protected and maintained at a
very high vacuum to avoid any interaction of the electron beam and the air particles.
The electron beam is finally focused on a viewing screen or a detector to collect images.
The following are the components of a TEM:
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Figure 2.14: Outline of a Transmission Electron Microscope. (A) CM200, an inhouse
200kV FEG instrument with Gatan-626 side-entry cryo holder (LN2 temperature) and
TVIPS F416 CMOS camera. Used to collect data in this dissertation. (Image Courtesy
: Philippe Ringler) (B) General outline of a TEM and its various components are
highlighted.
2.4.2.1 The gun
This is the source of the high voltage electron beam, which is the essence of a TEM.
Traditionally, the most common electron source used was tungsten or lanthanum hexa-
boride (LaB6). The electron source is superheated (3000◦C) by using an electric current,
until the energy of the electron is large enough to leave the metal. These escaped elec-
trons are accelerated with several hundred kilovolts (80-300 kV) by an electric field.
These electrons need to be collated into a coherent beam before they can be sent down
along the microscope column. In modern TEM, field emission guns (FEG) is now used,
where the tungsten filament is reduced into a small nanometer sized tip, thus producing
spatially and temporally more coherent and brighter electron beam.
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2.4.2.2 The lenses
The lenses in a TEM are composed of magnetic coils that generate a circular magnetic
field and helps focus the incoming electron beam. Three different set of magnetic lenses
are used in a typical TEM. The top most lens is called the objective lens and does the
very first step in focusing of the electron beam and image magnification. The next set
of lens is the intermediate lens, which functions to adjust and manipulate the required
magnification of the biological sample. The last part of lens system is a set of projector
lens, they are primarily used to focus and project the image on the visualising screen or
detector to collect images.
2.4.2.3 The apertures
Another important component of the TEM apart from the lenses are the apertures.
These apertures act like holes along the microscope column and function to limit and
control the size of the beam that can pass through them. They are present at different
location on the TEM and affect the function. The very first aperture is the condenser
aperture, which is located on the top of the column. The functions of the condenser
aperture is to condense the electron beam coming out from the electron gun and maintain
a coherence electron beam. The second aperture is located just below the sample, after
the objective lens. Its function is to control the generated contrast in the image by a
method called amplitude contract.
2.4.2.4 Detector
Traditionally all the high-resolution data collected in TEM were recorded on photo-
graphic films that needed further development and digitization. With the development
of CCD (charge-coupled device) cameras, the need to digitalization was obliterated and
faster and more automated data collection was possible but in terms of attainable reso-
lution from the data, photographic films still leaded. This was the limitation of how a
CCD works, where the electron from the TEM must be first converted to photos via in-
teraction with a scintillator. These multiple electron scattering events in the scintillator
restricts the quality of signal at high resolution and introduce extra noise to the images.
Very recently, this bottleneck in TEM has been overcome by the development of direct
electron-detection cameras (or direct detectors). These direct detectors are able to de-
tect electrons directly on a silicon wafer. They have a resolution and sensitivity greater
than film and have an added advantage of faster readout rate than CCD detectors.
Chapter 2. Introduction 41
2.4.3 Principles of EM image formation
In a transmission electron microscopy, images are formed from the very thin objects by
passing very high energy electrons through them. When the electron beam interacts with
the specimen in the microscope, there are three possibilities. If the electron does not
hit any atom of the specimen, it will continue to travel in the same line as the incident
beam of electron and hit the detector. The electron can come in contact of the matter
in the specimen and bounce off from the incident path without the transfer of energy
between the electron and the sample; this is called elastically scattered electrons. The
last possibility is when the electron can come in contact of the matter in the specimen
and bounce off from the incident path and transferring some energy to the sample, this is
called inelastically scattered electrons. The electrons can also interact with the specimen
and get reflected by an angle greater than 90◦, in that case they never reach the detectors
located at the end of the microscope. These type of electrons known as backscattered
electrons are generally not used in TEM. The inelastically scattered electrons are the
cause of noise in the TEM micrographs. The amount of energy that is transferred to
the sample by inelastically scattered electrons is variable and random, therefore when
these electrons hits the detector, the energy and the angle of incidence is unknown
causing noise. The elastically scattered electrons are the one that give contrast to the
TEM images and contain the high-resolution information. The amount of energy that is
transferred to the sample by inelastically scattered electrons is constant and according
to the law of conservation of momentum, the angle at which it will be reflected can
be determined. The contrast in the TEM images results from the interference of the
unscattered electrons beam with the elastically scattered electrons. This interference
can be constructive or destructive. To enhance the contract in the images the objective
aperture is used and functions by blocking the electrons that are deflected to a greater
angle. This is termed as the amplitude contrast and the most common imaging mode
in bright field EM.
2.4.4 CTF
As explained in the previous section, the images recorded in the TEM are phase contrast
images and can be considered good approximation of the specimen. As the electron
interacts very weakly with the light atoms of the biological specimen, it is impossible to
image the specimen at focus (the distance of the object from the focal plane). Instead
images are collected at slight under-focus or defocus, which imparts phase contrast to
the image. The mathematical functions that describe how this information is transferred
as a function of spatial frequency is called contrast transfer function (CTF). Essentially
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the images recorded on a TEM can be best viewed as the convolution of a real image
with a point spread function (PSF) of the microscope. CTF is an oscillation function
and some information is absent when it crosses zero and therefore it is impossible to
fully correct a single image taken at a specific defocus. Therefore, it is necessary to use
different defocus setting that results in the images having CTF with different zero at
varying spatial frequencies.
2.4.5 Negative stain
This is the most common method used in electron microscopy to generate contrast in the
biological sample inserted into the TEM. Staining is usually done with the use of heavy
metals such as uranium or molybdenum. The biological sample is deposited on an EM
grid and covered with the negative stain (e.g 2% uranyl acetate). The stain effectively
surrounds the sample. The heavy metals interact readily with the incoming electron
beam and generate phase contrast. When the electron beam passes through the sample,
it is deflected well by the stain and less by the volume occupied by the sample. This gives
a good contrast image, which can be inverted (hence negative) to reveal the projection of
the sample of interest. There are few drawbacks of this technique, firstly the structural
information contained in the projections of the particle is limited to the shape of the
molecule and suffer from distortion while drying of the stain or non-uniform staining of
the molecule. Secondly and most importantly, the resolution of negative stain images is
limited to approximately 20-25 and cannot be used to generate atomic information of
the biological molecule. But the simplicity of the technique makes it a popular method
still used actively.
2.4.6 Cryo-EM
To counteract the limitations of negative stain EM and preserve the native hydrated
structure of the biological specimen, unstained imaging methods are used. The high
vacuum of the EM can cause severe dehydration of the biological molecules and can
use collapse and distortion of the structure (Bremer et al., 1992). To avoid the use
of staining solution but still protect the sample, there are two widely used methods
to achieve this. First method is to replace the water of hydration that surrounds the
biological molecule with a less volatile medium such as sugars(glucose or trehalose),
first demonstrated by Henderson and Unwin (Henderson & Unwin, 1975). The second
method is the snap-freeze the sample in a very thin layer of vitreous ice, thus producing
a hydrated environment around the sample. This further requires the sample grid to be
kept at liquid nitrogen temperatures to maintain the vitreous ice around the particles
Chapter 2. Introduction 43
and also prevent the sample from some effects of beam damage. Low dose imaging
conditions are also employed for data collection in cryo-EM to cause least damage to
the sample. The resulting images has high-resolution information but very low signal to
noise ratio.
2.4.7 Image processing
The general steps of single particle analysis (SPA) are shown in Figure 2.15 and ex-
plained in the next sections. The schematic also shows the image processing used in this
dissertation to process electron microscopy data.
2.4.7.1 Particle picking
The very first step in single particle reconstruction is particle picking. In order to
reconstruct a 3D structure of a protein complex, it is necessary to combine several
thousands of experimental 2D projections (particles). These particles have to be picked
or boxed out from the recorded EM micrographs prior to the image processing. There
are manual as well as automatic particle picking softwares to perform this task. When
there are only few micrographs (for example in negative stain data), often the easiest
way is to visually inspect the micrographs and identify and single out all the projections
which looks like your sample by hand and thus avoiding any bad particle coming from
contaminations like stain or ice. But for bigger routine datasets when the number of
micrographs collected is in the range of few hundreds, it can be tedious to do manual
particle selection and one has to use automated particle picking softwares. There are
several different algorithms for picking particles from noisy EM micrographs based on
template matching, gaussian approaches and edge detection. There are several specific
softwares that use these algorithms in slightly different way.
2.4.7.2 CTF correction
EM images are typically acquired using defocus contrast. This along with the aberrations
inherent in the objective lens system of the TEM creates blurring of the acquired EM
micrographs, visible as a point spread function (PSF). These modulations when observed
in the reciprocal space by doing a Fourier transform of the image are more obvious and
the areas of positive values become visible as Thon rings (Thon, 1966). The combined
effect of the imaging conditions is termed as the Contrast transfer function (CTF). The
effect of CTF can be corrected mathematically as a function in reciprocal space. There
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Figure 2.15: Main steps involved in the single particle image processing, starting from
the raw micrograph to 3D model generation.
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are specialised techniques that are a part of single particle image processing to correct
CTF and these include phase flipping, amplitude correction and Wiener filtering.
2.4.7.3 2D Classification and Averaging
After picking the particles and correcting for the CTF, the next challenge in single
particle image processing is enhance the low signal to noise ratio (SNR) of the individual
particle images. The low SNR of the individual particles makes it hard to see any
structural features of the protein complex, therefore, similar particles that have the same
orientation are clustered and this process is called 2D classification. Once the 2D classes
are generated, all the particles of the same class can be averaged to enhance the SNR.
For high-resolution cryo-EM data, secondary-structure elements such as alpha helices
are easily seen in such class averages. 2D classification and averaging starts by alignment
of the particles. The picked particles are centered and positioned to allow locating the
correct in-plane rotation and translation along the x-y direction. This step places all the
particles in similar relative position that is prerequisite for clustering them into separate
classes. Both reference and reference free alignments of the particles are possible. To
avoid any kind of reference bias in the low SNR particles, reference free alignment is
mostly used. After the particles are nicely aligned, next task is to identify similar views
or orientation of the sample and group them together in separate classes. A method
called Multivariate statistical analysis (MSA) is used to perform this task. MSA works
by compressing the large EM data mathematically into eigen images and then common
features are identified within the eigen images via cluster analysis. Another popular
method to perform 2D classification is by maximum likelihood approaches where the
classification begins with a random set of reference images from the set of particles. Then
for each projection image, probabilities are calculated with respect to its translation,
rotation and the degree of matching with each reference. Subsequently rotated and
translated particles are formed and their 2D Fourier transforms, appropriately weighted
by the CTFs, are combined to form the overall average images. The new generated
averaged images now form the new references and the same procedure is iterated for
several rounds, resulting in a set of representative class averages.
2.4.7.4 Orientation determination
Once we have class averages of different views from the 2D projection of the particles,
the next challenge is to determine 3D orientation to these different class averages. There
are two approaches for this, angular reconstitution and projection matching.
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Angular reconstitution method is based on the central projection theorem that states
that the center of the Fourier transforms of any two-dimensional projection images of
the same object intersect at the center of three-dimensional Fourier space. Utilizing the
central projection theorem, the goal to determine the orientation is to find the overlap-
ping pieces (or common lines) of data. Applying central projection to single particle
analysis implies that if between two images there exist some overlapping data, and then
the corresponding relative orientation between those two images can be computationally
calculated.
Another method used for orientation determination is projection matching which can
be applied for any set of particles for which there is already previously determined
structure or a 3D model generated by other methods. The starting model is used to
generate simulated projections and these are then compared computationally with the
experimental projection images generated in class averages to determine the orientation
using cross correlation.
2.4.7.5 3D Reconstruction
Once we have the class averages and have assigned their relative orientation in 3D space,
they are all combined into one 3D model, this process is termed as 3D reconstruction.
The method used for 3D reconstruction is called weighted back-projection. In principle,
weighted back projection method is quite similar to inverse Fourier transform. In the
same way as a real space 2D Image is generated from a 2d Fourier space image by using
2D inverse Fourier transform, a weighted back-projection determines the real space 3D
volume of the protein complex from a series of 2D Fourier space images using a series of
transformation.
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3.1 Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative movement dis-
order. It affects 1-2% of all people above the age of 65 (Lees et al. 2009) and is at present
incurable, although treatments are available to alleviate the symptoms. Genetic studies
have identified several genes involved in PD pathogenesis. Of these, the leucine rich re-
peat kinase 2 (LRRK2) gene is a key gene, with mutant forms being the most prevalent
known causes of genetic PD and genomic variants at the LRRK2 locus are common risk
factors of sporadic PD (Hernandez et al. 2016). In addition, LRRK2 appears to act
upstream of several other PD genes and PD risk factors such as alpha-synuclein, tau,
cyclin G associated kinase (GAK) and RAB7L1 (Cookson 2015; Taymans and Cook-
son 2010). The 144 kb long LRRK2 gene encodes for the 2527 amino acid (aa)-long,
cytosolic enzyme LRRK2, which functions as a GTPase as well as a kinase. Most of
the pathologically important mutations are clustered in its catalytic core of this protein,
hinting that altered GTPase and kinase activities may play a crucial role in pathogenesis
(Zimprich et al. 2004; Bekris et al. 2010). Targeting the LRRK2 protein pathway is
currently regarded as one of the most promising approaches in drug development for PD
(Lee et al. 2012).
LRRK2 is a member of the ROCO protein family (Bosgraaf and Van Haastert 2003). It
has a multidomain organization containing several protein-protein interaction domains,
including armadillo (ARM), ankyrin repeats (ANK), leucine-rich repeats (LRR), Ras
Of Complex proteins GTPase (ROC), C-terminal Of ROC (COR), a kinase (KIN) and
WD40 (Mills et al. 2014). (Figure 3.1). LRRK2 is known to be involved in several
cellular functions including autophagy and neurite outgrowth regulation and related
to some mitochondrial diseases ((Gmez-Suaga et al. 2012) (MacLeod et al. 2006),
(Cherra et al. 2013)). Biochemical experiments suggest that LRRK2 kinase and GTPase
activities may be regulated by dimerization (Greggio et al. 2008; Danils et al. 2011;
Taymans 2012; Sen et al. 2009).
Three other ROCO proteins have been identified in humans: Leucine-rich repeat kinase 1
(LRRK1), death-associated kinase 1 (DAPK1) and Malignant fibrous histiocytoma am-
plified sequence 1 (MFASHI1). Out these, LRRK1 is the closest homologue of LRRK2.
The domain organization is similar, and like LRRK2, LRRK1 is known to purify as
homodimer (Civiero L et. al., 2012). LRRK1, a 2015 aa-long protein, lacks the ARM
domain and while the C-terminal region of kinase is present as in LRRK2 but it does
not correspond to a WD40 domain. Otherwise, the sequence identity and similarity
between the domains of the two proteins varies between 14% and 50% ( 3.1). Despite
this similarity, mutations in LRRK1 have not been linked to PD. This difference has
stimulated various studies to understand the functional roles of LRRK2 and LRRK1
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Figure 3.1: Predicted domains (Mills et al. 2014) are depicted with different col-
ors and their relative location is drawn to scale within the full-length protein: ARM,
armadillo repeats; ANK, ankyrin repeats; LRR, leucine-rich repeats; ROC, Ras Of
Complex proteins GTPase; COR, C-terminal Of ROC; KIN, a kinase; WD40, WD40
repeats. Below each domain, the sequence identity and sequence similarity is reported
in the column with same color.
and the link between the two (Taylor et al. 2007; Civiero and Bubacco 2012) (Reyniers
et al. 2014), (Dachsel et al. 2010), (Klein et al. 2009). Up to now, it has been a
challenge to isolate a sufficient quantity of intact, full-length LRRK2 or LRRK1 protein
for structural analysis. The available structural knowledge about LRRK2 comes from
the study of related ROCO proteins in lower organisms. Only crystal structures for the
ROC, ROC-COR and kinase domain have been published so far (Gotthardt et al. 2008;
Deng et al. 2008; Gilsbach et al. 2012). Although, these structures have advanced
our understanding of LRRK2 functions, the inferred functionality of the full-length pro-
tein is indirect. Similarly, structural information about LRRK1 is minimal with no 3D
structures reported, neither of full length nor of LRRK1 fragments. Thus, determi-
nation of the full-length structure of both LRRK1 and LRRK2 remains an important
goal to further our understanding of LRRK proteins in general as well as the structure
function relationships that contribute to pathological activity of LRRK2 in particular.
In this study, we report the first 3D structures of the homodimeric complexes formed
by full-length LRRK2 and LRRK1, respectively, analyzed by cryo-electron microscopy
(cryo-EM) imaging and computational single particle image analysis. Both, 2D analysis
of the two complexes and the 3D models (∼ 25 A˚ resolution), reveal a striking similarity
between the domain organization of LRRK2 and LRRK1.
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3.2 Materials and Methods
3.2.1 Protein expression and purification
The very first step to structural biology projects is to prepare protein with adequate
quality and quantity. Compared to x-ray crystallography, in cryo-EM the quantity re-
quired for data collection is much lower, i.e., in micrograms range compared to milligrams
required for making protein crystals. The protein of interest can be either purified from
a natural source or can be overexpressed artificially. Usually, the amount of protein nat-
urally produced in cells is far less for experimental work. For overexpression of proteins,
there are two kinds of broad choices, a prokaryotic expression system or a eukaryotic
expression system such as yeast, insect or mammalian cells. In prokaryotic or bacterial
expression systems, it is comparatively easier and faster to make the constructs and ex-
press proteins. But for big complex eukaryotic protein complexes, the lack of eukaryotic
post-translational machinery required for the post-translational modification and proper
folding of the target protein, often results in insoluble and aggregated protein. Yeasts
are single cell eukaryotes, which grow fast like bacteria and are also easy to culture,
but compared to bacterial system, yeast expression system contains eukaryotic post-
translational setup. The problem with yeast cell is the chitinaceous cell wall, which is
very difficult to lyse, and makes purification of cytoplasmic proteins troublesome. In
contrast, insect and mammalian cell expression system are much more time consuming
and expensive, and the resulting yield of the target protein is also lower. But the main
advantages of a mammalian cell expression system is that it provides the correct folding
of protein by performing the correct post-translational modifications such as carrying
out complex glycosylation, multi-subunit protein assembly and so on. Therefore, overex-
pressed protein from mammalian cell culture is much more closer to the natural protein
in the respect of the tertiary structure and biological function.
3.2.1.1 Constructs
Constructs for the mammalian expression of 3flag-LRRK1 and 3flag-LRRK2 included
the pCHMWS-3flag-LRRK1 and pCHMWS-3flag-LRRK2 constructs, described previ-
ously (Danils et al. 2011; Civiero et al. 2012). The protein expression and purification
of LRRK2 and LRRK1 from these constructs was carried out in Jean-Marc Taymans lab
in Leuven University and were shipped to our lab in Basel on ice bags (4 ◦C) through
FedEx. Another construct used for mammalian expression of 3flag-LRRK2 was the
p3XFLAG-CMV-10-LRRK2 (a generous gift from Prof. Takeshi Iwatsubo, described in
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(Ito et al. 2007)). This was send on ice through FedEx to setup LRRK2 expression and
purification in our lab in Basel (Figure 3.2).
Figure 3.2: Plasmid of LRRK2, features and restriction digest. (A) LRRK2 plasmid
used for expression and purification. (B)Rragments generated by restriction enzyme
EcoRI generated using virtual cutter tool in Serial Cloner v2.6 (C) Gel electrophoresis
of the restriction digest fragments.
For plasmid amplification, GenElute HP Plasmid Maxiprep Kit from Sigma were used.
Before using the kits, plating was carried out. 1.5 g of Bacterial Agar was measured in
a 500 mL conical flask and dissolved in 100 mL LB in microwave for a minute until it
was clear. After it got hand warm, 100µlof Ampicillin (100mg/mL Stock) was added to
this solution and poured into three petri dishes, evenly and left to get solidified. In the
meanwhile DH5 competent cells were thawed on ice. 2µlof diluted plasmid (2 ng/uL)
was added to 50µlof DH5 cells. They were further Incubated on ice for 15 min, followed
by heat shock at 42 ◦C in water bath for 30 seconds and further incubation on ice for 2
minutes. 250µlLB medium was added to it and shaken for 60 min at 37 ◦C on a shaker
@ 750 rpm. Around 10% of the total solution was pipetted out onto first agar plate. For
rest of the volume, the solution was spinned on a table centrifuge at a maximum rpm for
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12-13 seconds. The supernatant was removed and the pellet was resuspended and put
onto the second agar plate. Third plate was used as a control.The E. coli was spread
gently with sterile glass rod across the agar surface. The plates were incubated overnight
at 37 C. Making sure there are good colonies in plate, 5 ml of LB (Take 2 mL of LB if
you cant wait for the whole day) was added with 6µlAmp. antibiotic to a 100 ml conical
tube. A well-formed, smooth-edged, isolated colony on the agar plate was selected with
a sterile toothpick.The tip was then dipped into the LB medium, containing Ampicillin.
This was placed on a shaking incubator at 37 C, 200-250 rpm for 8 hours. Check after
3-4 hours, the medium should turn cloudy. 20µlof this starter culture was added to 500
mL LB and 600µlAmp in a 2 L conical flask and placed on a shaking incubator at 37
C, 180 rpm for overnight. The overnight culture was collected on ice and followed the
protocol for GenElute HP Plasmid Maxiprep Kit from Sigma to extract and purify the
amplified copies of plasmid. The final concentration of the plasmid was measured on
the NanoDrop 2000 spectrophotometer (Thermo Scientific).
Before using the shipped plasmid for protein expression and purification, a routine di-
agnostic restriction digest was performed on the plasmid to confirm its identity. Se-
rial Cloner v2.6 was used to view features and check restriction sites on the amplified
p3XFLAG-CMV-10-LRRK2 plasmid. Using the virtual cutter tool in the software,
fragments generated by restriction enzyme EcoRI were calculated. EcoRI was used
to carried out to digestion the plasmid and fragments were checked by electrophoresis
(Figure 3.2,B,C).
3.2.1.2 Cell culture and transfection
HEK293FT cells (Life Technologies) were cultured in 15 cm Corning petri dishes (Sigma),
at 37◦C in an atmosphere containing 5% CO2. The culture medium was comprised of
Dulbecco’s Modified Eagle’s Medium (DMEM), 10% fetal bovine serum, 0.1 mM MEM
nonessential amino acids (NEAA), 2 mM L-glutamax and 1 mM MEM sodium pyruvate.
The medium was changed every 2-3 days and cells were split at 90-100% confluence. Dur-
ing sub-culturing of fresh or thawed cells, the culture medium was supplemented with
500µl/ml Geneticin (G418). One day before transfection, ∼12.105 cells were plated out
on a single 15 cm petri dish. Transfection was induced by the addition of polyethylen-
imine (PEI) (Sigma); 30µg of plasmid (LRRK2 or LRRK1) and 60µl sterile PEI solution
(1 mg/ml, pH 7.0) were dissolved in 800µlDMEM (without additives) and added to the
petri dish. To check the efficacy of transfection of HEK293T cells, a petridish was
transfected with GFP plasmid in parallel to the LRRK1 and LRRK2 transfections and
checked in confocal microscope as a positive control.
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3.2.1.3 Protein Purification
The constructs for expression of LRRK2 and LRRK1 included the 3xFlag tag and the pu-
rification of LRRK2 and LRRK1 followed the two step affinity purification (Figure 3.3).
To start, 48 hours after transfection with LRRK1 and LRRK2 constructs, the cells were
rinsed with phosphate-buffered saline (PBS) and lysed in 1 mL lysis buffer (20 mM
Tris/HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 10% glycerol
and protease inhibitor cocktail (Sigma)), on ice, for 10 min. The collected lysate was
centrifuged at 4◦C for 10 min at 18280 g to remove cell debris. The supernatant was
incubated overnight with lysis buffer equilibrated anti-Flag M2 agarose beads (Sigma-
Aldrich) at 4◦C on a rotator mixer (STARLAB, Germany). Beads were washed four
times with wash buffer (25 mM Tris/HCl pH 7.5, 400 mM NaCl, 1% (v/v) Triton X-
100). Washing was done in batch by first pelleting the agarose beads by low speed
centrifugation (400g for 2 minutes at 4◦C) or allowing them to sediment at 4◦C (i.e.,
on ice). After the wash step, protein was eluted from the beads by adding 5 volumes
of elution buffer (20 mM Tris/HCl pH 7.4, 200 mM NaCl, 5 mM MgCl2 1 mM DTT,
0.02% (v/v) Triton X-100) with 100µg/ml of 3xflag peptide (Sigma) and rotating this
on a wheel at 4 degrees for 30 minutes (STARLAB, Germany). Afterwards, the beads
were spun down at 400 g for 2 minutes and supernatant containing the eluted protein
was collected. The purified protein was used straight away for EM analysis or stored in
50% glycerol in -20 ◦C for future use. All the buffer noted above were used before the
ProteoPlex screening buffer screening (next section), for LRRK2, new buffer conditions
were used for purification and data collection. For LRRK1, the above noted buffers were
used for purification and cryo-EM analysis.
3.2.2 SDS-PAGE and Silver Staining
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is a common
method used for separating protein mixtures according to their molecular mass by elec-
trophoresis. SDS is a strong ionic detergent that is used to denature the proteins and
decorate them with negative charges. A discontinuous polyacrylamide gel is used a as
a support medium. For LRRK2 and LRRK1, NuPAGE Novex 3-8% Tris-Acetate pre-
cast commercial gels were used (Life Technologies). These gels are designed for optimal
separation and resolution of large proteins (36 - 500 kDa) under denaturing gel elec-
trophoresis condition. Purified protein were mixed with 2x SDS loading buffer and left
at RT for at least 20 minutes before loading them into the gel. Heating the sample for
denaturing was avoided as it caused migration artifacts in the gel on staining. Gels were
inserted into the Bio-rad chamber gel kit and filled with NuPAGE Tris-Acetate SDS
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Figure 3.3: Workflow of the protein purification of LRRK2 and LRRK1.
Running Buffer (Invitrogen). 10 - 20 micrograms of protein per well are added, along
with molecular mass markers (Precision Plus Protein Dual Color Standards, 10-250 kDa,
Bio-rad) for size estimation. High voltage running condition were used for the pel at
35 mA for 1 hour. After electrophoresis the module was disassembled and the gel was
carefully removed.
Protein Gels were stained with Coomassie Brilliant Blue G (Sigma). The gel was placed
in solution containing 0.05% Coomassie, 50% methanol, 10% acetic acid, water and
placed on a shaking plate for 30 minutes to overnight, until the gel displayed a uniform
blue color. Once the staining is complete and the gel was no longer visible in the
dye solution, it was rinsed in distilled water and destained for 4 - 24 hours in 50%
methanol, 10% acetic acid, water. A paper or sponge was also used to absorb extra
dye. Destaining was done until the background was clear. Coomassie staining works
best to detect protein sample on the gel which as at least 100 ng per band. The yield
of LRRK2 was usually lower than 100 ng per band, therefore it was only visible in
coomassie stained gels when the yield was exceptionally good or concentration of the
protein was increased prior to SDS-PAGE. Therefore the gel were further stained by
silver staining method. Silver staining is a sensitive gel staining technique that utilises
the protein binding properties of silver ions, which are then reduced to silver metal
using a developing solution, creating a visible image. The primary benefit of silver
staining is its high sensitivity, as it is able to detect less than 1 ng of protein (Weiss
et al., 2009), making it extremely useful for applications involving low protein levels.
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For LRRK2 and LRRK2 the routine yield from different preparation was between 10-
20 ng/ml, silver staining was an appropriate staining method. For silver staining, the
first step is the fixation step where the gel after SDS-PAGE was placed in a solution of
Fixer 50% methanol, 12% acetic acid and water. Next is the sensitizing step, where the
gel was washed thrice in 30% ethanol solution for 20 minutes each, following 1 minute
incubation with solution containing sodium thiosulphate. The third step is the silver
reaction, where the gel was rinsed in distilled water thrice for 20 seconds each before
incubating in silver nitrate and formaldehyde solution for 20 minutes. The fourth and
the final step is the development of silver stain gel for which, the gel is rinsed briefly
in water for 20 seconds and placed in a sodium bicarbonate and formaldehyde solution
for few seconds to minutes and carefully inspected, until the bands starts to appear on
the gel. Immediately after that, the gel should be placed back into the starting fixing
solution to stop the gel form being overexposed.
3.2.3 Western Blotting
To perform western blotting, polyacrylamide gels after running SDS-PAGE were blot-
ted onto polyvinylidenedifluoride (PVDF) membrane in transfer buffer using the Fusion
FX apparatus from Witec AG. PVDF membranes were prepared by dripping them in
methanol solution for 1 minutes and placing in a transfer buffer comprising of Tris 50
mM, Glycine 40 mM, SDS 0,04%, Methanol 20%. A sandwich is prepared by wetting
filters and sponge pads before in the transfer buffer. Care has to be taken not to trap
any air bubbles between filter paper, gel and membrane, which would hinder protein
transfer. The sandwich was placed in blotting apparatus with blotting membrane fac-
ing the positive pole for wet blotting for 1-2 hours at 30 Volts, 200 mA. Afterwards,
the module was disassembled and the membrane was labelled for orientation of loaded
samples. For subsequent immuno-probing, unspecific binding sites were blocked by plac-
ing the membrane in phosphate buffered saline (PBS) blocking buffer containing 0.1%
Tween 20, 5% nonfat dry milk for 30 min to 2h at RT or overnight at 4◦C. The blocking
solution was removed and the membrane was then incubated for 3h at room tempera-
ture to overnight at 4◦C with primary antibody, anti-LRRK2 antibody [MJFF2 (c41-2)]
(Abcam) at an appropriate dilution of 1:1000, in PBS, 0.1% Tween 20, 5% nonfat dry
milk. The PVDF sheets are washed in PBS and 0.1% Tween 20 (three to four times for
10 min) at room temperature. Incubation with secondary antibody, anti-rabbit IgG -
peroxidase antibody produced in goat (Sigma) at 1:20.000 dilution in incubation buffer
followed. The blots were washed in PBS, 0.1% Tween 20 or PBS, 0.1% Triton (three to
four times for10 min) at room temperature and rinsed in PBS.
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For detection enhanced chemiluminescence plus (ECL+) technique (Amersham Phar-
macia Biotech, Little Chalfont, England), was used. The reagent consists of two com-
ponents, enhanced luminol reagent and oxidizing reagent, that are mixed in a 1:1 ratio
shortly before use. The membrane was lightly blotted against tissue paper after washing
to remove excess liquid and then incubated with 1 ml detection agent for 1 min. Ex-
cess detection solution was removed with tissue paper. The membrane was transferred
into a film cassette, covered with plastic foil and exposed to an X-ray film (Hyperfilm,
Kodak) in a darkroom. The film was exposed for a few seconds up to 30 min or longer
depending on the amount of protein to be detected. Films were developed in a Fusion
FX apparatus from Witec AG.
3.2.4 Liquid chromatography-mass spectrometry (LC-MS)
Purified LRRK2 samples were prepared for LC-MS analysis by dissovling in a lysis buffer
(2% sodium deoxycholate(SOC) in 100 mM ammonium bicarbonate) in the volume two
times bigger than the volume of protein sample. 1µl TCEP buffer was added per 40µl
protein extract. It was vortex for 10 sec and then ultrasonication of samples was done
for 2x10 sec with a vial Tweeter. (Samples were put on ice between steps) The samples
were then heated for 10 minutes at 95◦Cat 1000 rpm. The samples were allowed to cool
down and spin down at 10,000 rpm for 10 sec. This was followed by protein digestion
by trypsin was added to the samples to a final protein ratio of 1:50 and digested at
37◦Covernight. Trifluoroacetic acid TFA was added to a final concentration of 1%. The
SOC in the sample precipitated and the samples were centrifuged at 14000 rpm for
30 min at 4 C. The supernatant was transferred to a new tube and it was centrifuged
again at 14000 rpm for 15 min at 4 C. The supernatant was then used for solid phase
extraction.
The C18 columns were conditioned with 150µl acetonitrile at 1600 rpm for 30 sec and
this step was repeated 2 times. Then the columns were equilibrated 2X with 150µl buffer
A at 2400 rpm for 30 sec. The samples were then loaded and spin into a new tube at
1800 rpm for 2 minutes. The flow through was reloaded and spin again at 1800 rpm for
2 minutes. The columns were then washed 3X with 150µl◦Cat 2400 rpm for 30 sec. The
bond peptides were eluted into new tubes with 2X 150µl buffer B at 1600 rpm for 30
sec. The eluted peptides mixture were concentrated under vacuum to dryness for 1-2
hours. The peptides were dissolved in LC-MS/MS LC buffer A right before use; using
1X5 sec ulltrasonication and shaking it at 1400 rpm at 25◦C for 5 minutes before LC-
MS/MS analysis. The final concentration of peptide was adjusted to 0.5 ug/uL using
LC- buffer A. The samples were filled into LC vial (minimum 10µl, better 20µl) and the
air bubbles were removed either by shaking the vials or a short centrifugation at low
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rpm. The samples were then stored at -20◦C before they are analysed at the LC-MS
instruments at the Proteomic Core Facility at the Biozentrum, University of Basel. The
data generated from the LC-MS was analysed in Scaffold Software version 4.4.
3.2.5 Grafix
Purfied LRRK2 were subjected to stabilization in a continuous glycerol/glutaraldehyde
gradient by the GraFix method (Kastner et al. 2008). Using gradient master (Biocomp
Instruments) a continuous 10-30% (vol/vol) glycerol gradient in 4 mL centrifuge tubes
(Beckman). 120µlof the sample were applied on the top of the tube, together with
0.025-0.1% glutaraldehyde and allowed to settle for 1h at 4◦C. As a control, sample was
also applied into a similar glycerol gradient without the cross-linking agent, which were
later used for LC-MS analysis to determine the presense of LRRK2. Centrifugation was
performed at 34,000 rpm in a SW 60 Ti-Rotor rotor (Beckman) for 14 h at 4 ◦C. After
centrifugation, 300 µl fractions were collected from the top of the tubes and 80 mM
glycine pH 8.0 to quench the cross-linking.
3.2.6 Sample optimization by ProteoPlex screening
One of the major challenges in cryo-EM and other structural biology approaches in gen-
eral is to obtain purified macromolecules in an intact and stable manner. Most of the
macromolecular complexes amiable for cryo-EM analysis are composed of several indi-
vidual biomolecules or a single protein is consists of several individual domains. These
complex assemblies are often prone to dissociation and aggregation. This imparts con-
formational heterogeneity in the purified protein. Therefore, optimisation of the sample
preparation for cryo-EM is a crucial step and can often be limiting step towards getting
a 3D structure to interrogate their function within cells. ProteoPlex is a new method
that is based on Differential scanning fluorimetry (DSF), which can aid in the study of
stability of your interest of protein complex as a function of buffer conditions. DSF is
a method that has been used successfully in x ray crystallography studies to determine
stabilizing buffer conditions and measure ligand interaction of single chain proteins.
Proteoplex take the methodology further and develop a new thermodynamic framework
to incorporate complex unfolding curves which are characteristic of macromolecular as-
semblies. In ProteoPlex, small amount of protein is used to screen a range of buffer
conditions at different pH in a 96-well plate together in the present of a fluorescent dye.
The whole system is heated up and upon subsequent unfolding of the protein sample;
the hydrophobic side chains in the residues are exposed, which results in the dye getting
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hyperfluorescent. As the concentration of the unfolded protein is increased, the pro-
tein starts getting aggregated and the hydrophobic residues are hidden from generating
fluorescence signal (Figure 3.4). Hence the melting temperature of the protein in that
particular buffer composition can be determined and is related to the stability of the
protein. The higher is the needed melting temperature, the more stable is the protein.
Figure 3.4: Basics of ProteoPlex : Representative unfolding transition as obtained
by ProteoPlex or DSF. The transition consists of three phases. (i) In the native state,
proteins or macromolecular complexes do not interact with the dye Sypro orange. (ii)
In the unfolded state, exposed hydrophobic regions bind Sypro orange, causing the
dye to become hyperfluorescent. (iii) During the aggregation phase, the proteins or
macromolecular complexes interact with each other and compete for dye-binding sites,
leading to a decrease in fluorescence. (Chari et al., 2015)
During the purification, a few aliquots of anti-Flag M2 agarose beads with bound LRRK2
were not treated further, but stored in storage buffer (20 mM Tris/HCl pH 7.4, 200 mM
NaCl, 5 mM MgCl2 1 mM DTT, 0.02% (v/v) Triton X-100, 50% glycerol) and shipped
on ice (4◦C) for ProteoPlex analysis. The ProteoPlex assay was performed in a 96-well
plate as explained in (Chari et al. 2015); the 20-µl reaction mixtures contained different
buffers at various pHs (Table S1). Following the outcome of ProteoPlex screening, new
optimum buffers were used during the purification of LRRK2 for binding and elution of
pure protein. LRRK1 was purified with buffers as noted in previous section.
3.2.7 Electron microscopy
For negative stain transmission electron microscopy (TEM), 3.5 µl of purified protein
sample was pipetted onto a glow-discharged, carbon-coated copper grid and left to ad-
sorb for 1 minute. The grid was then washed on three droplets of milliQ water, and
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subsequently stained on two droplets of 2% uranyl acetate for another 1 minute, blot-
ting between each step. Grids were scanned using a Philips CM10 TEM (FEI Com-
pany, Eindhoven, The Netherlands) operated at 80 kV under low-dose conditions (20
electrons/A˚2). Images were collected at a nominal magnification of 96,000x at various
defocus values between -0.5 to -1.5 µm, and recorded with a 2K Veleta side-mounted
TEM CCD camera (Olympus), corresponding to a pixel size of 3.8 A˚ at the specimen
level.
For cryo-EM, 3.5 µl of the purified protein sample was pipetted onto a glow-discharged,
holey carbon films (Quantifoil R2/2, Quantifoil Micro Tools, Jena, Germany) with an
additional thin layer of carbon, and left to adsorb for 1 minute (Figure 3.14, B). The
grids were then rapidly plunge frozen in liquid ethane, cooled by liquid nitrogen, using
a MarkII Vitrobot (FEI, Eindhoven, Netherlands). The frozen grids were transferred
to a Gatan-626 cryo-holder. Micrographs were recorded under low-dose conditions (25
electrons/A˚2) on a CM200 TEM (FEI Company, Eindhoven, The Netherlands) operated
at 200kV with 58,000x nominal magnification. Data was collected using a TVIPS F416
CMOS camera (TVIPS, Gauting, Germany). The range of defocus used for collecting
micrographs was between -1 to -2.5 µm.
3.2.8 Image processing
The EMAN2 software suite (Tang et al. 2007) was primarily used. Particles, i.e.,
image of LRRK2 or LRRK1 complexes, were boxed out interactively from the negative
stain TEM or cryo-EM micrographs using the e2boxer interactive procedure. Contrast
transfer function (CTF) correction was accomplished by producing high-pass filtered
phase-flipped particles, using the e2ctf program. Reference-free class averages were
generated using the e2refine2d program, requesting the generation of 128 classes with a
maximum of 100 particles per class. Initial models were produced with the e2initialmodel
utility from the best 2D class averages (10 in all), both without imposed symmetry and
with imposed C2 symmetry. The final 3D maps were refined using the standard iterative
projection matching, class-averaging and Fourier reconstruction procedure of EMAN2.
The resolution of each reconstruction was determined by the gold standard Fourier shell
correlation criterion. UCSF Chimera (Pettersen et al. 2004) was employed to visualize
and analyze the final maps. For comparison, after the CTF correction in EMAN2 the
particles were fed into the Relion software (Scheres 2012) and compared. Using the
newly incorporated e2refinetorelion2d functionality in EMAN2 (Bell et al. 2016), same
particles as processed in EMAN2 were exported and run for 25 rounds of 2D reference-
free class refinement in Relion 1.2 with 128 classes in total.
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3.3 Results and discussion
3.3.1 Purified LRRK2 and LRRK1 are unstable for longer period
At the beginning of the project, purification of LRRK2 and LRRK1 was carried out in
the research group of Jean-Marc Taymans at University of Leuven, Belgium and shipped
in small aliquots on ice (Figure 3.5). Proteins were aliquoted and shipped at 4 ◦C in two
different ways: Purified proteins eluted in elution buffer (20 mM Tris/HCl pH 7.4, 200
mM NaCl, 5 mM MgCl2 1 mM DTT, 0.02% (v/v) Triton X-100) and non-eluted protein
bound to anti-Flag M2 agarose beads stored in storage buffer (20 mM Tris/HCl pH 7.4,
200 mM NaCl, 5 mM MgCl2 1 mM DTT, 0.02% (v/v) Triton X-100, 50% glycerol). The
latter was washed in normal elution buffer several times to remove any traces of glycerol
which not suitable for cryo-EM sample preparation and eluted with 3xflag peptide to get
purified protein. The shipping time for the protein aliquots ranged between 2-3 days.
The aliquots where the protein LRRK2 and LRRK1 was already eluted and purified,
negative strain grids were made straightway to test the protein quality. The particles
appeared mostly aggregated on the grids and the quality was not good. Cryo-EM grids
were also made for the same sample but the similar aggregation was observed. When
the silver stain of the protein preparation was compared with the particles from EM,
the protein sample looked much more cleaner on the gel with good quality and no major
contamination. We suspected the LRRK2 and LRRK1 to be unstable on ice for a longer
period post their elution during the shipping. Next, we checked the aliquots of LRRK2
and LRRK1 which were shipped in 50% glycerol still bound to anti-Flag M2 agarose
beads. After the washing and elution steps which took 1 hour, the purified proteins
were used to prepare negative stain and cryo-EM grids. Less aggregates were visible in
the preparation and some particles were clearly seen in the negative stain which were
corresponding well the the expected size of the proteins. It was clear that the protein is
much more stable during the shipment when bound to the anti-Flag M2 agarose beads
and presence of 50% glycerol also protected the protein from aggregation. Therefore it
was decided for all the subsequent shipments of LRRK2 and LRRK1 from Jean-Marc
Taymans lab in Belgium will be non-eluted protein aliquots. One challenge that was
still present with the protein samples shipped bound to the anti-Flag M2 agarose beads
is the lack of correlation between the purity of the preparation as shown by the silver
stain gel and the quality of particles in the negative stain grids. Even when the sample
was very pure on the gel, it looked very heterogenous in the negative stain grids with
some aggregates. The discrepancy between the silver stain gel and the negative stain
EM images could be attributed to the shipment process as the sample used for silver
staining were instantly denatured with sodium dodecyl sulfate (SDS) for silver staining
while the protein could only be eluted for the EM analysis after 2-3 days of shipping
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time. Although in some preps the particles looked reasonably homogenous and some
data was cryo-EM collected to perform single particle image processing, the majority of
the shipments looked too heterogenous to collect more EM data. For the preps where
the quality was good and there was no presence of contaminants observable in the gel,
reproducible negative staining grids and cryo-EM grids were not possible, and hence, to
troubleshoot if the problem is arising from the quality of the sample degrading on ice
during the shipment time or from other factors, it was decided to setup the expression
and purification of LRRK2 in-house in the lab in Basel, to minimise the time between
the elution of purified protein to sample preparation for cryo-EM and negative stain
EM. For LRRK1, the sample quality was comparatively better than that of LRRK2 and
the shipped aliquots were only used to collect cryo-EM data for 3D reconstruction.
Figure 3.5: Purity and concentration assessment of 3flag-LRRK1 and 3flag-LRRK2,
shipped form Leuven, by silver stained SDS-PAGE. (A) A representative gel form one of
the purification preparation shipped on ice from Leuven. 3flag-tagged proteins adsorbed
to anti-flag M2 agarose beads were eluted with 3flag peptide. Eluted samples are in
lanes 7-8 and correspond to about 10 ng/µl of protein. Lanes Lanes 5-6 has anti-flag
M2-agarose beads. Lanes 1-4 shows BSA at 5, 10, 20 and 40 ng/µl. (B) Montage of
silver stained SDS-PAGE of all the purification preps for LRRK2 and LRRK1 send
from Leuven. The quality, purity and yeild varied between different preparations.
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Cell cultures for HEK293 cells was setup in our lab in Basel and transfection efficacy of
the cells was tested by transfecting some cells with a green fluorescent protein (GFP)
plasmid. The cells expressed the GFP well for the same transfection condition to be
used for LRRK2 (Figure 3.6,A). LRRK2 expression and purification was optimised and
checked with silver stained SDS-PAGE (Figure 3.6,B). Quality and yield of the purified
protein was reproducible and matched well with that from Leuven (compare with Fig-
ure 3.5). Further to be sure if the purified band on SDS-PAGE, corresponding to the
size of LRRK2 is inded LRRK2, western blotting was performed and LRRK2 presense
was confirmed (Figure 3.6,C).
3.3.2 Buffer optimization by ProteoPlex screening
The production of protein in high yield and purity is a prerequisite for structural analysis
by cryo-EM (Glaeser 2015). Each 15cm Petri dish of the cell culture yielded approx-
imately 50µg of purified protein. This was sufficient for initial negative stain TEM
imaging, and for cryo-EM if the Quantafoil grids employed were coated with an ad-
ditional carbon film. Pooling the cell lysate from several Petri dishes and eluting the
protein in less volume (see Materials and Methods) resulted in protein concentrations
for LRRK2 and LRRK1 as high as 0.7 mg/ml (Figure 3.14, A). Ultra-centrifugal filter
devices could not be used to concentrate either protein, because both tended to precip-
itate and bind to the membrane material. Although the concentrated purified protein
sample was used immediately to minimize any degradation with time and silver stain
gels showed it to be pure, negative stain TEM revealed a very heterogenous mixture of
particles. The difference clearly indicated that LRRK2 is unstable in the buffer system
used, Tris/HCl pH 7.4.
ProteoPlex analysis (Chari et al. 2015) was used to determine the buffer conditions that
gave the highest binding of LRRK2 to the agarose beads during purification, and those
that were best for the elution step and protein stability. ProteoPlex uses sparse-matrix
screening of a proteins thermal unfolding behavior in under various conditions to find the
optimum buffer system and pH. Similar methods using differential scanning fluorimetry
are routinely used in X-ray crystallography to optimize the quality and quantity of
protein sample for further crystal screening (Reinhard et al. 2013), but so far have
rarely been used for cryo-EM studies. All buffers used in the LRRK2 screens contained
0.02 % of Triton X-100 (see below). Proteoplex 88 buffers screen was carried out and
state transition graphs were recorded for each buffer condition. While performing the
buffer screen, 3xFLAG-LRRK2 bound to M3 agarose beads. Substantial peak were
detected between 20 and 45◦C (Figure 3.7,A). Hepes buffer at pH 6.8 was the most
favorable for protein extraction by agarose beads (Figure 3.8A). Following the findings,
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Figure 3.6: Expression and purification of full-length 3xFlag
LRRK2.(A)Representative confocal image of HEK293T cells transfected with a
GFP plasmid used as a positive control. (B)Silver stained gel of purified LRRK2. The
protein concentration was roughly 10µg/ml (comparition from the BSA concentration
markers in the first three lanes). There are strong bands at the molecular weights
expected for LRRK2, respectively indicating highly pure protein fractions. The silver
stain is slightly overexposed and the contamination visible at lower molecular weights
are overrepresnted. (C) Western blot analysis of LRRK2 probed with anti-LRRK2
primary antibody followed by detection with goat anti-rabbit secondary antibody.
Markers are in kilodaltons
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new purification of LRRK2 was carried on using Hepes pH 6.8. We tested the new buffer
conditions, together with control with binding buffer pH 7.5 by doing negative stain EM
of the new purified LRRK2 at binding buffer pH 6.8. A drastic change in sample quality
was observed ( Figure 3.10A and B). There was a slight increase in the purity of the
purified protein as seen in the silver stained SDS-PAGE, few impurities which were
present in the purified LRRK2 with binding buffer at pH 7.5 were absent in the purified
LRRK2 with binding buffer at pH 6.8 (Figure 3.10E). Next, the purified LRRK2 carried
out with binding buffer of Hepes pH 6.8 was again used to perform ProteoPlex buffer
screening for the elution buffer. When the same buffer as that of the binding buffer
was used to elute the protein, state transition calculated by ProteoPlex were very weak
but visible. I could not be excluded that the weak observable state transition might
be due to the agarose beads that are left after the elution. Also there were protein
aggregates visible in the graphs during the elution(Figure 3.8,B). Therefore, the elution
conditions were also optimized as they are different from binding conditions. Proteoplex
88 buffers screen was carried out and state transition graphs were recorded for each
buffer condition (Figure 3.7,B). Hepes buffer at pH 8.2 was found to provide the best
conditions for elution of LRRK2 (Figure 3.9). A fresh purification of LRRK2 was started
based on the new elution buffer conditions as well as the binding buffer condition form
the first ProteoPlex experiment. In parallel, a control LRRK2 purification using old
binding buffer and elution buffer conditions at pH 7.5 and pH 7.4 respectively, was also
carried out. Negative stain grids were prepared to assess the quality and improvement in
the particles were remarkably visible. A few aggregates were still visible on the negative
stain TEM micrographs, but most of the complexes were intact and the background
was much cleaner (Figure 3.10C and D). Based on the silver stained SDS-PAGE, a mild
improvement in the purity was observed as well (Figure 3.10F).
3.3.3 Detergent is required for LRRK2 to remain correctly folded.
To maximize SNR, any unnecessary buffer components should be avoided. For mem-
brane proteins, the detergent takes a significant toll on contrast (see Figure 2D, right
panel). In addition by reducing surface tension the detergent changes the way in which
the sample spreads on the support.
It is a well known fact in Cryo-EM, that any unncessary buffer components should
be avoided in during the sample prepartion to maximize the SNR in the micrographs
(Cabra et al. 2015). One such susbtance that was present in LRRK2 final elution
buffer, which impacted the contract in the collected images was detergent. For a soluble
protein, its unlikely to have detergent in the protein buffer, they are required mainly
for membrane protein. In addition by reducing the surface tension of the buffer they
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Figure 3.7: Proteoplex 88 buffers screen for binding buffer optimsation(A) and elution
buffer optimisation(B)
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Figure 3.8: Binding buffer optimization by ProteoPlex screening: (A) Melting curve
profiles obtained for LRRK2 in the presence of top four buffer systems. (B) Melting
curve profiles when the same buffer system is used for elution of LRRK2. The arrows
marks the aggregation of protein observed. Y axis is relative fluorescence and x axis is
temperature.
Figure 3.9: Elution buffer optimization by ProteoPlex screening: Melting curve pro-
files obtained for LRRK2 in the presence of top three elution buffer systems. Y axis is
relative fluorescence and x axis is temperature
change the way in which protein sample spreads on cryo-EM grids during the blotting
steps of vitrification, they also change the way. We tested removal of detegent form
the elution buffer of LRRK2 and tested by negative stain. If detergent was not present
in the final buffer used to elute the protein on purification, the shape of the protein
changed drastically. Negative stain TEM of this preparation revealed mostly globular
particles, rather than elongated particles with features (Figure 3.11). This indicates
that detergent is essential for LRRK2 to remain correctly folded, and that the detergent
might be stabilizing hydrophobic amino acid residues on the surface of the protein. The
observation is consistent with reports that LRRK2 associates with membranes (Alegre-
Abarrategui et al. 2009; Saha et al. 2009; Schapansky et al. 2014; Biskup et al. 2006).
It suggests that LRRK2 has an affinity for lipids. The effect of detergent on LRRK1
was not tested but owing to the similar domain organization to LRRK2 and overlap of
cellular functions, similar effect is likely to be expected.
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Figure 3.10: Buffer optimisation by ProteoPlex: (A)-(B) Comparison of particles
in negative stain TEM micrograph of LRRK2 purified in the regular binding buffer
(Tris/HCl pH 7.5) vs LRRK2 purified in the ProteoPlex suggested binding buffer (Hepes
pH 6.8) (C)-(D) Comparison of particles in negative stain TEM micrograph of LRRK2
eluted in the regular binding buffer (Tris/HCl pH 7.4) vs LRRK2 eluted in the Pro-
teoPlex suggested elution buffer (Hepes pH 8.2) (E)-(F) Silver stained SDS-PAGE of
purification of LRRK2 in different buffers used in (A)-(D) Scale bars: 100 nm.
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Figure 3.11: Effect of detergent on LRRK2 structure.: Negative stain TEM images
of LRRK2 eluted using in 20 mM Tris/HCl pH 7.4, 200 mM NaCl, 5 mM MgCl2, 1 mM
DTT A. Without the addition of detergent; almost all of the particles have a globular
appearance and structural details are not visible. B. With 0.02% of Triton X-100; many
of the particles have an elongated shape and some structural detail is evident. Dimeric
sides-views are clearly visible (inset). However, there are also some globular particles
demonstrating that even in the presence of detergent the protein is not completely
stable in the Tris buffer employed. Scale bars: 100nm.
Different types of detergent were also tested in place of the Triton X detergent which was
originally used in the all the buffers during the process of protein purification. The de-
tergents that we tested were n-decyl--D-maltopyranoside (DM), NP-30, Lauryl Maltose
Neopentyl Glycol (LMNG) and Tween 20. The concentration of these detergents in the
elution buffer were kept same as that of Triton, 0.02%. The silver stained SDS-PAGE
of the purified LRRK2 in different detergents revealed that the quality of the purified
protein doesnt change with the change in detergent (Figure 3.12). Some difference in the
quantity of the purified protein as observed with NP-40 and Tween 20, where a slightly
higher yield of the purified protein was seen as compared with control preparation with
Triton X detergent. The change in the yield was marginal and comes from the slight
different surface tension of these detergents which can promote the elution of protein
from the M3 agarose beads with 3xflag peptide during the rotation on the wheel before
the final elution. If the surface tension of the detergent is higher, the mixing of the
3xflag peptide with the the M3 agarose beads is not fully efficient and leads to lower
yield of the purified protein. As far as the shape and structure of the LRRK2 particles, a
clear difference was not seen between using different detergents (Figure 3.13). Therefore,
0.02 % of Triton X detergent was continued to be used during the purification steps of
LRRK2.
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Figure 3.12: Silved stained SDS-PAGE of LRRK2 purified with different detergents.
(A) n-decyl–D-maltopyranoside (DM) (B) NP-30 (C) LaurylMaltose Neopentyl Glycol
(LMNG) (D) Tween 20. The concentration of these detergents in the elution buffer
were kept same as that of Triton, 0.02%.
3.3.4 Cryo-EM of LRRK2
The time between elution of purified LRRK2 and cryo-EM grid preparation was kept
minimal (60 minutes). The presence of 0.02 % of detergent in the final elution buffer
(20 mM Tris/HCl pH 7.4, 200 mM NaCl, 5 mM MgCl2 1 mM DTT, 0.02 % Triton
X-100) complicated sample preparation for cryo-EM because of the reduced surface
tension of the liquid. After application of the sample to holey carbon grids, blotting
and plunge freezing, protein particles were only present on the thick carbon mesh, and
none in the vitreous ice regions spanning the holes (Figure 3.14,B). Neither increasing
the protein concentration ten fold, nor using Lacey grids, which have mesh-like openings
of different sizes and shapes, helped. However, coating the grids with a thin carbon
film and adsorbing the protein to this, resulted in a suitable distribution of the protein
on vitrification (Figure 3.14, A). These grids were imaged by cryo-EM and processed
by single particle analysis. The required use of an additional continuous carbon film
on one hand improves particle distribution but can cause particles to display preferred
orientations, leads to CTF determination based on the carbon film and not on the
particles, and is adding additional image noise from the carbon film to the micrographs.
We minimized at least the last problem by using a very thin layer of carbon (5nm).
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Figure 3.13: Negative stain microgrpahs of LRRK2 purified with different detergents.
(A) n-decyl–D-maltopyranoside (DM) (B) NP-30 (C) LaurylMaltose Neopentyl Glycol
(LMNG) (D) Tween 20. The concentration of these detergentsin the elution buffer were
kept same as that of Triton, 0.02%.
Elongated particles with two-fold symmetry could be easily seen in the raw micrographs
of negatively stained preparations (Figure 3.15, A). To obtain a 3D model, about 18280
particles were selected from the 265 micrographs and subjected to reference free align-
ment and classification as detailed in the Materials and Methods. The 128 class averages
generated (Figure 3.15 and Figure 3.16,A) show that the LRRK2 dimeric complex has
high degree of conformational flexiblity and lies in an ensemble of different conformations
each giving a different projection in the cryo-EM images. This makes 2d averaging very
difficult.Nevertheless, few class averages showing the side-views of the particles were very
characteristic, being ∼17nm long, ∼10nm-wide with a clear 2-fold symmetry, indicating
that the LRRK2 complex is a dimer (Figure 3.15). The dimensions are consistent with
previous estimates (Civiero et al. 2012). The two monomers interact at both ends of
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Figure 3.14: Effect of detergent in the buffer on vitrification of sample in cryo-EM (A)
LRRK2 purified at a relatively higher yield of 0.7 mg/ml The usual yield per protein
purification was 0.01 mg/ml. (B) Typical holey carbon copper grids used for Cryo-EM
sample preparation(Above) and addition of an extra thin layer of carbon on top of the
holey carbon layer (C) LRRK2 sample as imaged in a holey grid. The zoomed inset
shows that all the LRRK2 particles are stuck to the carbon on the edges of the holes
and none in the vitrified ice. (D) LRRK2 sample as imaged on a holey grid with an
additional layer of carbon. Particles are spread evenly throughout the hole with carbon
giving a darker contrast to the backround. Scale bars: 100nm for the micrographs
their protein cores, which together seem to form a small cavity. The ends of the com-
plex are less distinct, which is a sign that these domains have intrinsic flexibility. To
validate the analysis, the same dataset was also processed with Relion software package
(Scheres 2012), which uses a Bayesian approach to infer the parameters of a statistical
model from the data. The resulting class averages are very similar to those obtained by
EMAN2 processing (Figure3.16).
To improve the structural flexibility of LRRK2 in order to get more defined class aver-
ages, we used the GraFix method (Kastner et al. 2008). GraFix is a robust technique
that combines glycerol gradient centrifugation and limited glutaraldehyde crosslinking
that is used to improve the stability of globular protein complexes. It a popular method
that has been used successfully and has more than 160 citations. It aims to rigidify
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Figure 3.15: Cryo-EM and single particle processing of LRRK2 and LRRK1. (A)
LRRK2 complexes in Hepes buffer at pH 8.2, imaged by cryo-EM. Right: EMAN2
class averages showing characteristic side-views of the complex. These views are ∼17nm
long and ∼12nm wide. Their two-fold symmetry indicates that the complex is a dimer.
(B) LRRK1 complexes in Tris buffer at pH 7.4, imaged by cryo-EM. Right: EMAN2
class averages showing characteristic side-views of the LRRK1 complex. These are very
similar to corresponding side-views of LRRK2 but slightly smaller, being ∼16nm long
and ∼10nm wide. Again they indicate that the complex is a dimer. Scale bars: 100nm
for the micrographs, 10nm for the averages.
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the macromolecules by mild crosslinking without inducing major structural rearrange-
ments. The benefit of running the sample on a gradient centrifugation is also to frac-
tionate different oligomerization states and remove smaller impurities. We use purified
LRRK2 and subjected to 14 hours of gradient ultracentrifucation using glutaraldehyde
as a crosslinker. In parallel LRRK2 was also subjected to same gradient ultracentrifu-
cation but without adding any crosslinkers. Fractions were collected corresponding to
different sizes manually. The LRRK2 fractions without the crosslinker were used for
LC-MS detection. In all the four fractions corresponding to the size of LRRK2 dimer,
mass spectrometry values detected the presence of LRRK2. The cross-linked LRRK2
fractions were imaged in negative stain and the micrographs looked much better with
more homogenous particles, clear background and monodisperse population without any
aggregates (Figure 3.17, A). Similar quality of the particles were seen in the unfix frac-
tions as well (Figure 3.17, B). As the the gradient used for GraFix has glycerol, the final
protein had more than 10% glycerol, this made cryo-EM of the GraFix sample impossi-
ble, without buffer exchange. We used spin desalting columns for buffer exchange but
as with our earlier experience with using ultra-centrifugal filter devices, LRRK2 tend to
stick to the pores and it formed more aggregates in the final buffer exchanged fractions.
As cryo-EM was not possible, negative stain data was collected form the GraFixed frac-
tion which showed the maximum mass-spectrometry value form LC-MS. A total of 40
microgrpahs were collected and a total of 1864 particles were picked form the micro-
graphs and subjected to single particle 2D classification. The class averages displayed
similar size of the particles we expected but the shape of the particles were very dif-
ferent(Figure 3.17, C). A probable cause of this is the vast conformational flexibility of
the complex and the crossliking is unable to lock one particular conformation but rather
cross-links random residues which are in closer proximity. A recent study has reported
large experimentally observed distance distribution widths of ∼3 nm for all positions
in the catalytic core of the RocCor tandem in LRRK2 bacterial homolog. Infact, the
same group published the crystal structure of Roc-COR tandem for the first time and
in the crystal structure of the dimer, electron density for the second Roc domain in the
RocCOR dimer was missing (Gotthardt et al., 2008). They now attribute this missing
density to the large conformational flexibility inherent in ROCO protein catalytic do-
main, which sample multiple conformations, one of which seems to be represented by
their published RocCOR crystal structure. A very similar conformational flexibility can
be expected with the LRRK2’s catalytic domain which is highly conserved in all Roco
proteins.
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Figure 3.16: The total data set contained 18280 LRRK2 particles. (A) The 128
reference free class averages obtained after 5 iterations in EMAN2 using e2refine2d
program. The best classes from these are shown in Figure 3.15,A and subsequently
used to generate and refine the initial 3D model for LRRK2. (B) The 128 reference
free class averages obtained after 25 iterations in Relion. The class averages shows
structural heterogeneity among particles. Below: Selected examples. The shape and
dimensions of the particles are very similar to that obtained with EMAN2. Scale bar,
10nm
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Figure 3.17: GraFix treatment of LRRK2. (A) Best fraction from GraFix performed
on LRRK2 (B) Same fraction complimentary to (A) but without crosslinking agent.
Inset shows a zoomed view of the particles in both the images. (C) 31 classes of LRRK2
GraFix particles from fraction in (A) generated by reference free 2D classification in
EMAN2. Scale bar, 100nm
3.3.5 Cryo-EM of LRRK1
For LRRK1, all the EM analysis was done from the purified protein samples send from
Leuven. Relative to LRRK2, the total concentration was usually always greater than
that of LRRK2, which meant for the same number of micrographs collected for LRRK1,
total number of particles for single particle analysis was always be greater than that of
LRRK2. Also just by visual inspection of negative stain images from very new prep, it
appeared that LRRK1 is more slightly more stable than LRRK2. This was a great moti-
vation for this project and for the future structural studies of LRRK2 as well because the
high homology between LRRK2 and LRRK1, makes studying LRRK1 equally impor-
tant to gain structural and mechanistic information for LRRK2, which is more difficult
to work with.The same procedure as that for LRRK2 was used to prepare and analyze
LRRK1 for cryo-EM. For initial EM analysis and build a starting 3D model, around
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684 particles were selected from 50 micrographs, aligned without the use of a reference
and classified into 64 classes containing a minimum of 100 particles using EMAN2 (Fig-
ure 3.15,B). As the dataset used for class averages for LRRK1 was much smaller than
that of LRRK2,the number of particles per class was lower which resulted in LRRK1
class averages that did not look quite as crisp as their LRRK2 counterparts, but the
characteristic dimeric side-views as seen for LRRK2 were clearly visible (Figure 3.15,B).
These side views show that LRRK1 too forms a dimer with very similar overall shape
to the LRRK2 dimer, but slightly smaller in dimensions. As might be expected from
the identical domain organizatoin of the two sequences (Figure 3.1). Another differ-
ence observable form the class averages are the protrusions at the ends of the LRRK1
complex, which have slightly less prominent arms. From the 2D class averages, a not
of information that differentiates the LRRK2 and LRRK1 structures cannot revealed,
rather more and more similarities are seen. The fuzzy appearance of the class averages
also hints towards a similar conformational flexibility inherente in LRRK1 dimer.
3.3.6 Low resolution 3D model
The initial 3D model for both LRRK2 and LRRK1 using C1 (no symmetry) and C2
(two-fold symmetry) were in good agreement, which was evident from the dimeric shape
of the complexes. Using the initial model as reference, iterative projection-matching
reconstruction was applied with C2 symmetry. After three rounds of refinement the
final reconstruction was produced at a resolution of 24.2A˚ and 24.3A˚ for LRRK2 and
LRRK1 respectively (Figure 3.19A,B). Both LRRK2 and LRRK1 complexes have sim-
ilar overall shape (Figure 3.18). They form elliptical homodimers with each monomer
having a concave shape. Compared to LRRK1, LRRK2 displays slightly more curvature.
Two dimerization contacts are visible in the low-resolution map. These two dimerization
points are at roughly equal distance from the center of the plane between the monomers.
The structural similarity of the two complexes observed in this low-resolution reconstruc-
tion does not contradict the idea that heterodimers might form in vitro, as postulated
by Dachsel et al. (Dachsel, 2010).
3.3.7 Conformational heterogeneity in LRRK2
So far the efforts for single particle cryo-EM analysis of full length LRRK2 and LRRK1
was performed without the addition of any ligand or substrate. But as both proteins
functions as active GTPase and Kinases with the Roc-COR and Kinase domain re-
spectively, effect of substrate binding on the conformational heterogeneity was tested.
The Roc-COR domain is the characteristic of the Roco family of proteins, which has
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Figure 3.18: 3D reconstructions of the homodimeric LRRK1 and LRRK2 complexes:
(A) 3D model of LRRK1 (blue) at 25 A˚ resolution showing two side-view orientations,
the lower one being 90 degrees rotated relative to the upper one. (B) 3D model of
LRRK2 (red) at 25 A˚ resolution showing the side-view orientations, the lower one
being 90 degrees rotated relative to the upper one. (C) Cut-away of LRRK1 (blue) and
LRRK2 (red). The plane of the slice is perpendicular to the dimeric plane, to show
how the dimer forms. Scale bar: 10nm
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Figure 3.19: Resolution curves for the LRRK2 and LRRK1 3D models.: (A) The
resolution of the LRRK2 is 24 A˚ using the gold standard 0.143 FSC cutoff criteria .(B)
The resolutios of the LRRK1 is 24 A˚ using the gold standard 0.143 FSC cutoff criteria.
been characterised to belong to the class of G-proteins activated by nucleotide-dependent
dimerization (GADs) (Gasper et al., 2009; Terheyden et al., 2015). Conventional guanine
nt-binding proteins (G proteins) cycle between a guanosine triphosphate (GTP) -bound
and guanosine diphosphate (GDP) -bound state with the help of regulatory proteins.
The GDP-bound state is the off state while GTP-bound state is considered the active
on state. There are two other important class of proteins that play a crucial functional
role, these are GTPase-activating proteins (GAPs) and the guanine nucleotide-exchange
factors (GEFs). GAPs functions by complementing and stabilizing the active site to
increase the rate of GTP hydrolysis while GEFs speeds up the nucleotide exchange and
accelerate the release of GDP or GTP. In contrast of these, GADs like LRRK2 and
LRRK1 show show reciprocal complementation of their active sites and seem not to
require GAPs and GEFs. The nucleotide-regulated switching cycle is therefore is car-
ried out by the elements within the protein complex (Gasper et al., 2009). Further,
the need for GEFs for nucleotide exchange is not necessary as these proteins exhibit
low nucleotide affinity and dimerize upon GTP binding to supplement each other with
elements needed for efficent GTP hydrolysis, hence not requiring the accessory roles of
GAPs. For LRRK2, it has been a challenge to study its G-protein cycle (Gilsbach and
Kortholt, 2014). A few GAPs and GEFs has been reported for LRRK2 but none of
these putative regulators directly bind to the Roc domain. Therefore purified LRRK2
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were incubated with GTP and GDP and analysed by negative stain EM to see the effect
on the structural stability of the protein complex in the various state GTPase cycle.
LRRK2 was purified as usual, GTP and GDP were added to the solution at the final
elution step together with 3xFlag peptides for 30 minutes. Purified LRRK2 without the
addition of GTP or GDP was also prepared as a control for comparison. The purity
of the preparation and yield of the protein was not changed much with the addition
of the GTP and GDP as observed in the silver stained SDS-PAGE (Figure 3.20,F). In
the negative stain images, LRRK2 particles without GTP/GDP look heterogenous with
several different population of particles (Figure 3.20,E). In comparison, the particles
with bound GTP and GDP looked less heterogeneous with particles resembling less
conformational flexibility as judged by the similar shape of the particles. The GTP and
GDP bound LRRK2 samples were kept on ice for 1 hour and negative stain grids were
prepared again to compare the degradation of the sample with time. It was noticed
while the sample without the bound GTP and GDP started degrading, for GTP and
GDP bound LRRK2 still looked more homogenous after 1 hour. At the level of negative
stain particle images, it is not possible to confirm if there are different conformation in
the LRRK2 GTP and GDP bound forms but visual comparison of the particle quality
between non bound LRRK2 clearly shows much more heterogeneity. Similar test was
done with addition of ATP (Figure 3.21).
These findings are consistent with a recent study done with the Roc-COR tandem in
bacteria Chlorobium tepidum using site-directed spin labelling and pulse EPR distance
measurements to measure conformational changes during the Roco G-protein cycle (Rudi
et al., 2015). The RocCor domain is highly conserved between all the ROCO protein
family members. The study revealed that the Roc G-domains are highly mobile enti-
ties, sampling multiple conformations. Unlike other G-proteins, Roc-COR dimer was
identified to exist in open and closed conformations but instead, sample multiple con-
formations and the binding of different nucleotides lead to complex alteration of the
occupancies of the conformational states. It can be postulated that a similar structural
and activation mechanism should occur for the Roc-COR domain for LRRK2 as well.
The negative stain images shows improvement in heterogeneity in the GDP and GTP
bound LRRK2. Although a great deal of small functional conformational flexibility still
exist within the particles but the large scale conformational flexibility is reduced by the
availability of the nucleotide.
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Figure 3.20: Negative stain micrographs of LRRK2 bound with GTP and GDP: (A)
LRRK2-GTP at 0 hour of incubation (B)LRRK2-GDP at 0 hour of incubation (C)
LRRK2-GTP at 1 hour of incubation (D)LRRK2-GDP at 1 hour of incubation. (E)
LRRK2 without any bound GTP or GDP. (F) Silver stained SDS-PAGE of purified
LRRK2 with GTP, GDP and withtout any ligand.
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Figure 3.21: Negative stain micrographs of LRRK2 bound with ATP: (A) LRRK2-
ATP at 0 hour of incubation (B) Silver stained SDS-PAGE of purified LRRK2 with
ATP.
3.4 Conclusions
An efficient culture of HEK293 cells transfected with LRRK2 and LRRK1 3xflag tagged
protein was established to express the full length proteins followed by affinity based
purification to yield good quality and quantity of protein. The quality of purified parti-
cles was further optimised for cryo-EM sample preparation by doing ProteoPlex buffer
screening to identify the best buffer condition for binding and elution of the protein.
The effect of detergent was also tested on the sample quality and integrity of LRRK2
structurally by preparing negative stain EM grids. It was found that detergent is essen-
tial for LRRK2 to remain correctly folded, and that the detergent might be stabilizing
hydrophobic amino acid residues on the surface of the protein. This supports the claim
in other studies which found LRRK2 association with membranes. Cryo-EM data col-
lection was carried out for both full length LRRK2 and LRRK1. The quality of particles
on the cryo-EM grids were optimised and it was possible to easily see elongated parti-
cles with two-fold symmetry. Several cryo-EM micrographs were collected to carry out
computational single particle analysis on the data. 2D class averaging on the individual
LRRK2 and LRRK1 particles confirmed the homo dimeric form of both the complexes.
The heterogeneity in the class averages and the blurry appearance in the periphery sug-
gested the inherent flexibility of the dimeric complexes. The two monomers appeared to
be interacting at both ends of their central protein core, which together seem to form a
small cavity. The ends of the complex are less distinct, which is a sign that these domains
have intrinsic flexibility. The 2D class averages of both LRRK2 and LRRK1 appeared
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very similar in shape, size and overall organisation, with notable difference of LRRK1
being slightly shorter and the protrusions at the ends of the LRRK1 complex have less
prominent arms. Based on the 2D class averages, an initial low resolution model was
generated to seed the iterative 3D reconstruction process. After few rounds of refinement
the final 3D reconstruction was produced at a resolution of 24.2A˚ and 24.3A˚ for LRRK2
and LRRK1 respectively. Both the complexes, have very similar overall shape. They
form elliptical homodimers with each monomer having a concave shape. Compared to
LRRK1, LRRK2 displays slightly more curvature. Two dimerization contacts are visible
in the low-resolution map. These two dimerization points are at roughly equal distance
from the center of the plane between the monomers. The apparent convergence of the
3D refinement to low resolution final maps for LRRK2 and LRRK1 prevented further
structural analysis of the full length density map by fitting atomic models of the indi-
vidual domains. This also highlights the high degree of flexibility within the protein
complex and controlling the conformational diversity of the complex by binding with a
substrate will be imperative for further high resolution cryo-EM steps. In conclusion,
we present the first structural insight into full length LRRK2 as well as LRRK1, which
will further assist follow-up work towards a high-resolution structure of these important
molecules.
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4.1 Introduction
Genome-wide sequence studies estimate that 20-30% of all expressed gene products
are membrane proteins (Fagerberg et al. 2010). Biological membranes act as barriers
between cells and their environment as well as in between intracellular organelles. The
basic unit of most membranes is phospholipids, but in addition they also contain a large
portion of proteins. These membrane proteins embedded within the lipid bilayer can
make up 50% the mass of a biological membrane. Thereby, membrane proteins are
involved in various vital processes such as energy transport during photosynthesis or
respiration, transport of molecules across the membranes via channels or transporters,
transmission of chemical signals, anchoring of the cytoskeleton and catalyze chemical
reactions. Considering the pivotal role of membrane proteins in various cellular functions
makes them of great medical importance. It has been estimated that of all the available
drugs, more than 50% of them act on membrane proteins (Arinaminpathy et al. 2009).
Despite their importance, however, their structural studies remain challenging, which
is evident from the fact that only less than 2% of all the known proteins structures
published in protein data bank (PDB) constitute the membrane proteins. Studying
the dynamics and the structure of the membrane proteins not only provides important
insight to the molecular mechanism of their function but also aids in rational design of
novel drugs (Lounnas et al. 2013).
In contrast to cytoplasmic proteins structure determination, the robust technique of
X-ray crystallography is challenging in case of membrane protein as they are difficult
to purify in large amounts and hard to obtain well-diffracting three-dimensional crys-
tals. Electron crystallography of membrane proteins has from the start proved to be
an alternative approach to obtain structures of membrane protein. Electron crystal-
lography requires much less material than X-ray crystallography methods and has the
added advantage of providing a native environment to the membrane proteins. To obtain
highly ordered 2d crystals for electron crystallography data collections, detergent solu-
bilized purified proteins are reconstituted into artificial phospholipid bilayer membrane
by carefully adjusting the favourable buffer conditions during controlled detergent dial-
ysis (Figure 4.1,A). Once well ordered 2d crystals of membrane proteins in lipid bilayer
are obtained, they can be vitrified or embedded in sugar to be imaged in TEM (Fig-
ure 4.1,B). Computational image processing of the micrographs and electron diffraction
data is utilized to further reconstruct the 3d structure of the protein at high resolution.
Although, electron crystallography aims to provide a more native lipidic environment to
the membrane protein, mimicking the conditions in cellular membranes, a major caveat
in electron crystallography is that the membrane proteins are imagined as flat crystal
sheets surrounded by same buffer (Buffer A in Figure 4.1), unlike in between a typical
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gradient which occurs across the membrane in cells. There is always a different ion
concentrations on either side of the membrane which cause a potential difference across
it, known as the membrane potential (typically -40 to -80 mV). This gradient can also
arise due to the difference in salts, pH and ligands. Many membrane proteins undergoes
conformational changes to perform their biological function like transport and signalling
owing to the change in this gradient across the membrane. Therefore to truly mimic
the true native functional state of the membrane protein, it is necessary to maintain
a gradient across the lipid membrane while imaging membrane protein 2d crystals by
Cryo-EM.
Figure 4.1: Schematic for electron crystallography of membrane proteins and vesic-
ular 2D crystals: (A) The basic principle of 2D crystallization of membrane proteins.
(B) Vitrification for cryo-EM data collection of 2D crystals (Above) and vesicular 2D
crystals (Below). Vesicular 2D crystals have the advantage of using two different buffer
system, inside and outside.
To achieve this goal, we extended the methodology of electron crystallography and used
liposomes to reconstitute the membrane proteins. The advantage of using liposomes
is that we can control the environment of inside and the outside of the liposomes by
altering the buffers to provide a more native gradient to the reconstituted membrane
proteins. Membrane proteins embedded in such liposomes can therefore be captured in
action and more closer to their native functional forms (Figure 4.1,B). The general idea
is to put forward a method to study the structure of 2D crystalline membrane proteins
while they are embedded in specific buffer solutions. The membrane protein will first
be purified and crystallized in buffer ”A”, and the buffer on the outside of the vesicular
crystals will be changed to buffer ”B” via column filtration prior to vitrifying the grids
for cryo-EM data collection.
There are four major challenges to establish and optimise this method for any membrane
protein : preparation of liposomes with different buffer solution inside and outside ;
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reconstitution of membrane proteins in such liposomes ; Cryo-EM of 2D crystals as round
vesicles ; and 3D reconstruction of the vesicular 2D crystals. The membrane protein that
we used as a test is MloK1, a bacterial transmembrane protein which works as a voltage
gated potassium channel, modulated by cyclic nucleotides. Our lab already determined
three-dimensional (3D) maps of MloK1 at 7A˚ resolution in the presence and absence
of its ligand, cAMP (Kowal et al. 2014). A mechanism of channel gating upon cyclic
nucleotide binding was formulated from the observed conformational change between the
two models in the presence and absence of cAMP. Reconstituting MloK1 into liposomes
and adding ligand to the buffer outside of the vesicles will in effect introduce the same
conformation change. In addition compared to classical electron crystallography, this
method will have two additional advantages. Firstly to generate a 3D model, there is no
tilting of the specimen required as the spherical geometry captures the protein projection
in all possible orientation. Secondly, as MloK1 forms 2D crystals in 180-degree screw-
axis symmetry (p4212), it will place adjacent membrane proteins in alternating up/down
orientations in the membranes, allowing us to determine the 3D structures of oppositely
regulated states in one experiment.
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4.2 Methods
4.2.1 Liposomal Preparation
Two types of of lipids were used for preparing the liposomes : Polar extract phospholipids
from E. coli and 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC). Both the lipids
were purchased from Avanti Polar Lipids, Inc. There were different methods used for
preparation of liposomes, buffer encapsulation and exchange. (Figure 4.2).
Figure 4.2: General scheme of lipsosome formation, encapsulation and buffer gradient
formation.
4.2.1.1 Film dispersion method
Liposomes were prepared by using the film dispersion method. The preparation starts
by transferring lipids in chloroform into a glass tube. Lipids were always stored in -20
by sealing tightly by a teflon tape. The lipids were kept at room temperature for 15
minutes and thereafter, the solvent was evaporated by a stream of argon gas. A film
of lipid was formed inside the glass surface at the bottom. The lipids were then kept
under vacuum for 30 min while it is still pumping. Afterwards, the vacuum vent was
closed, motor pump stopped and the lipids were kept overnight to remove any trace of
the solvent. Based on the experiment the concentration of lipid take ranged from 5 to
10 mg/ml. Next day, the lipid film were rehydrated using an aqueous desired buffer
that resulted in spontaneous swelling to form multilamellar vesicles (MLV) and large
unilamellar vesicles (LUV).
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4.2.1.2 Dialysis
For making liposomes by dialysis, 1 ml of the lipid - detergent mixture was loaded
into dialysis buttons and dialysed against detergent-free buffer (20mM Tris-HCl pH 7.6,
20mM KCl, 1mM BaCl2, 1mM EDTA) for at least 24 hours. Following dialysis the
liposome mixture was extruded 11 times through a polycarbonate filter of pore size of
100 or 200 nm, in a mini extruder (Avanti). The extrusion helps to maintain a uniform
distribution of size and attain unilamellar vesicles.
4.2.2 Liposomal Encapsulation
Fluorescent dyes and other material at 100mM concentration were used for liposomes
encapsulation experiment. 1 mL of the encapsulating buffer or dye was added to the
glass tube with lipid film. The tube was vortexed until no lipid film is seen sticking to
the glass tube walls.
4.2.2.1 Column Gel Filtration
To prepare a column for gel filtration, sephadex G-25 resin were hydrated in 20mM Tris-
HCl pH 7.6, 20mM KCl, 1mM BaCl2 and 1mM EDTA to form a slurry. The buffer was
mixed well with the slurry and allowed to settle. After the slurry settles, the extra buffer
was decanted and the process was repeated 2-3 times. The column was then packed with
the slurry and equilibrated with the same buffer 2-3 time again. The liposomes were
passed through the column, eluted with the same buffer and different fractions were
collected. Another method that was used to to exchange the buffer and remove non
encapsulated material from the liposomes was ultracentrifugation. Liposomes encap-
sulated with a desired buffer were centrifuged at 70,000 rpm in TL100 ultracentrifuge
(Beckman) for 1 hr at 4◦C. A thick pellet of the liposomes at the bottom of the ultra-
centrifuge tube was observed and the supernatant containing the unencapsulated buffer
was removed. The pellet was resuspended with the new desired buffer to be present in
the outside of the liposomes.
4.2.3 Protein Purification - MloK1
Intact, full-length, cyclic nucleotide-modulated potassium channel MloK1 was expressed
and purified as described in a recent publication (Kowal et al. 2014). The C-terminal
hexahistidine-tagged MloK1 construct was transfected into E. coli cells (BL21(DE3)).
These transformed cells were grown in L-broth at 37 ◦C, and the expression was induced
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with 0.2 mg/ml anhydrotetracycline for 2h, as the OD600 reached 0.7. Sonication was
used to pellete and lysed the cells. 50 mM n-decyl--D-maltopyranoside (DM, Anatrace)
was used to solubilize the membrane proteins. Purification of MloK1 was done in two
steps, first over a Co2+-affinity chromatography and then with gel-filtration chromatog-
raphy (Superdex 200, GE).
4.2.4 Protein Reconstitution in Liposomes
For reconstitution of purified detergent-solubilized MloK1, two methods were used: Dial-
ysis and Bio-beads. For dialysis, detergent-solubilized MloK1 in purification buffer was
mixed with E. coli polar lipid extract at different lipid-to-protein ratio ranging from 1
to 10. It was further dialysed against detergent-free buffer (20 mM Tris–HCl pH 7.6, 20
mM KCl, 1 mM BaCl2, 1 mM EDTA) in small dialysis buttons for 1-2 days at room
temperature. Another method used for membrane protein reconstitution in liposomes
was using biobeads. Biobeads are insoluble hydrophobic polymer beads that interacts
with the hydrophobic tail of detergent molecules. The rate of binding is rapid and the
detergent coated beads can be removed easily by sedimentation or centrifugation. We
started by mixing detergent-solubilized MloK1 and desired amount of E. coli polar lipid
extract according to different different lipid-to-protein ratio that was needed to be tested
in small vials. To these few microlitres of biobeads were added using a blunt cut pipette
tip were added and left for 3-4 hours at room temperature. The protein reconstituted
vesicles are tested in EM and the sample was carefully transferred and stored in fresh
vials, leaving the biobeads.
4.2.5 Cryo-EM
For cryo-EM, 4 µL of the liposomes was pipetted onto a glow-discharged, holey carbon
films (Quantifoil R2/1, Quantifoil Micro Tools, Jena, Germany). Using a fast blotting
time of 1 second and a bolting force of 1, the grids were then rapidly plunge frozen
in liquid ethane, cooled by liquid nitrogen, using a MarkIV Vitrobot (FEI, Eindhoven,
Netherlands). The frozen grids were transferred to a Gatan-626 cryo-holder. Micro-
graphs were recorded under low-dose conditions (25 electrons/A˚2) on a CM200 TEM
(FEI Company, Eindhoven, The Netherlands) operated at 200kV with 58,000x nominal
magnification. Data was collected using a TVIPS F416 CMOS camera (TVIPS, Gaut-
ing, Germany). The range of defocus used for collecting micrographs was setup enough
to see the lipid bilayer of the liposomes in the projections.
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4.3 Results and Discussion
4.3.1 Liposome Encapsulation
The very first goal of the project was to make liposomes with a gradient across the
lipid bilayer. To achieve this liposomes were prepared and encapsulated with a desired
buffer while on the outside a different buffer is present. For the ultimate goal of cryo-
EM data collection of such liposomes, visualizing the buffer gradient across liposome
in TEM images was also critical. The liposome preparation and encapsulation method
should therefore sustain three important properties - Liposomes should not leak the
encapsulated content. Liposomes should not burst or contract due to osmotic pressure.
Liposomes should be able to undergo vitrification for Cryo-EM. To visualize the buffer
gradient across the liposomes we added a marker in the inside buffer that was used
during liposome formation and encapsulation, while the outside buffer that was used in
the subsequent washing step was absent of the marker. These liposomes having a buffer
gradient were imaged by Cryo-EM. We tested several different markers.
4.3.1.1 Carboxyfluorescein
Carboxyfluorescein is a well known fluorescent dye commonly used as a tracer agents.
The dyes being membrane-impermeant can be incorporated into liposomes, and has been
used routinely in pharmaceutical studies where it allow for the tracking of liposomes as
they pass through the body using fluorescence microscopy. We tested if a small amount
of carboxyfluorescein added to the buffer inside the liposomes can be visualised using
cryo-EM. In cryo-EM images, it was not possible to observe any change in grayscale value
between the inside dye-rich buffer and outside buffer. Similar results were achieved with
caesium chloride (CsCl) and ferric chloride(FeCl3) (Figure 4.3)
4.3.1.2 Gold Nanoparticles (GNPs)
GNPs are the colloidal suspension of gold particles of nanometer sizes and are routinely
used in cryo-electron tomography as fiducial markers for tomograph alignements. We
used GNPs of 10nm size with the encapsulating buffer and washed the liposomes using
size exclusion chromatography to remove unencapsulated GNPS. The cryo-EM images
shows a possible leakage in the liposomes with free GNPs visible outside the liposomes.
A possible cause of the leakage of GNPs is the detergent coating which commercially
available GNPs comes with. To test this, GNPS were incubated with Antibody to
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Figure 4.3: Cryo-EM image of encapsulated fluorescent dye and heavy metal chemi-
cals: (A)Control liposome with no encapsulating material. (B) Liposome encapsulated
with Carboxyfluorescein (CF) (C) Liposome encapsulated with caesium chloride (CsCl)
(D) Liposome encapsulated with ferric chloride(FeCl3. Inset displays a zoomed view of
the liposomes. Scale bars:100nm.
form GNP-Antibody conjugates. This lead to aggregation of GNP-Antibody conjugates.
(Figure 4.4)
4.3.1.3 Bovine serum albumin (BSA)
BSA is a serum albumin protein derived from cows. It is available commercially and
used as a protein concentration standard in biochemical experiments. We used different
concentration of BSA to encapsulate in the liposome. Size exclusion chromatography
was used to exchange outside buffer and remove free BSA. The liposomes sustained vitri-
fication and fully BSA encapsulated liposomes were observed. At protein concentration
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Figure 4.4: Cryo-EM image of encapsulated gold-nanoparticles (GNPs). (A) GNPs
does not get encapsulated fully and a most of them stick to the carbon on the EM grids
(B) GNP-Antibody conjugates aggregated (C) Affect of size exclustion chromatography
(SEC) on the liposomes encasulated with GNPs and BSA. One left are the liposomes
before SEC and on right are the liposomes after SEC. Scale bars:100nm.
less than 10mg/ml, the content in the liposomes is more difficult to visualise. There was
no leakage of the liposomes. (Figure 4.5)
When BSA and GNPs were used together to encapsulate into the liposomes. After size
exclusion chromatography, there were no GNPs inside the liposomes while the BSA was
still present, which further supports the fact that the GNPs are permeable through lipid
membranes.
4.3.1.4 Other proteins : Apoferritin and Urease
Using another protein apoferritin at higher concentration of around 10 mg/ml better en-
capsulation is achieved. Urease at slight lower concentration (2.5 mg/ml) was also used
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Figure 4.5: Cryo-EM images of encapsulated BSA. (A) BSA at 33 mg/ml (B) BSA
encapsulated in liposomes at three different concentration 5 mg/ml (left), 10 mg/ml
(middle) and 50 mg/ml (right). Scale bars:100nm.
and partial encapsulation was achieved as indicated by yellow arrows used to show en-
capsulated urease and black arrows for the non-encapsualted urease outside the lipsomes
(Figure 4.6).
4.3.2 Reconstituting protein in buffer gradient liposomes.
After establishing methods to make liposomes and establish a buffer gradient between the
inside and outside of the liposomes, the next task was to reconstitute membrane protein
into the liposomes and make proteoliposomes. We used purified detergent solubilized
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Figure 4.6: Cryo-EM images of encapsulated apoferritin (A) and urease(B). Scale
bars:100nm
MloK1 to be reconstituted into the liposomes. We tested different lipid to protein ratios
(LPRs) which affects the growth of 2D crystals. We noticed at lower LPR (1 or less) very
large crystals are formed. We increased LPR to 5 and 10 to generate small crystalline
vesicles. The liposome preparation, protein reconstitution and vitrification, all can affect
the quality of proteoliposomes and therefore a lot of conditions has to be tested and
optimised. There are often proteoliposomes aggregates visible in the sample and the
shape of few proteoliposomes is distorted and not perfectly spherical. Another problem
at higher LPR is the presence of semi-crystalline vesicles where the reconstitution of
MloK1 was partial (Figure 4.7,A), this was evident with the lack of diffraction spots
emerging from these liposomes when their fourier transform is calculated. Only perfectly
crystalline vesicles displays the diffraction spots that are characteristic of MloK1 crystal
packing. The intensity of the diffraction spots was very low due to the curvature of the
liposomes (Figure 4.7,B).
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Figure 4.7: Cryo-EM images of liposomes reconstituted with MloK1 (A) Optimisation
of MloK1 reconstitution in lipsomes with changing lipid to protein ratios (LPR), some
examaples of non perfect proteoliposomes are shown (B) Perfectly crystalline vesicular
MloK1 liposomes at LPR of 10, on right a Fourier transform of the crystalline patches
from the proteoliposomes with weak diffraction spots. Scale bars:100nm.
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4.4 Conclusions
With the technological advancement in the field of cryo-em in the last few years with the
additional of powerful direct electron detectors and the software enhancements, there
is a need for novel sample preparation method to take advantage of this technological
advancement. Here we demonstrated a proof of principle for the use of liposomes as
a tool to study membrane proteins under buffer gradients by cryo-EM. Liposomes not
only provides an ideal near native lipidic environment to the membrane protein but
can easily be exploited to establish a buffer gradient across the lipid bilayer thereby
mimicking the true physiological conditions present in the cell. We showed it is possible
to make unilamellar vesicles by hydration and dialysis methods of smaller sized diameter
(<200um) which can be vitrified for cryo-EM. Using column gel filtration, we exchanged
the outside buffer of the liposomes to establish a buffer gradient. We showed that the
use of fluorescent dyes and heavy metal chemicals does not provide contrast in the cryo-
EM images and therefore fails to serve as a marker to visualise buffer gradient. There
is a possibility of leakage and bursting of the liposomes during the blotting step of
vitrification, therefore we used proteins like BSA, apoferritin and urease as a marker.
The encapsulated liposomes with buffer containing these marker proteins but absent
in the outside sustained vitrification. Next, we used the bacterial potassium channel
MloK1 as a test membrane protein to reconstitute into the liposomes in order to make
crystalline proteoliposomes. We tested various different LPRs to find the best conditions
for making perfectly crystalline MloK1 vesicles.
Chapter 5
General Discussion and Outlook
This dissertation was mainly committed to gain structural insight into the full length
protein complex by using cryo-EM and single particle image processing. The project
initially started as a collaborative project with the lab of Dr. Jean-Marc Taymans in
Leuven, Belgium. In the initial phase of the project, purification of LRRK2 and LRRK1
was carried out in Leuven and shipped on ice to Basel. With several testing, it was con-
cluded that both the protein LRRK2 and LRRK1 were not stable over time. To minimise
the time between protein purification and preparation of cryo-EM grids, HEK293 cell
culture and protein expression was setup in Basel starting with the LRRK2 plasmid.
Within a relative short period of four months, purification of LRRK2 was fully optimised
with similar quality as that was purified in the Taymans Lab in Leuven. Another ad-
vantage of the in house protein purification was the increase in yield that could be easily
achieved by upscaling the purification. The time between the elution of purified protein
and grid preparation for negative stain EM and cryo-EM could be reduced to less than
one hour, which avoided protein from aggregating but the problem of heterogeneity was
still present. To address the heterogeneity in the sample, ProteoPlex buffer screening
was employed. ProteoPlex uses sparse-matrix screening of a protein’s thermal unfolding
behavior in under various conditions to find the optimum buffer system and pH, similar
to differential scanning fluorimetry used in X-ray crystallography. The binding and the
elution buffer for LRRK2 were kept at around pH 7.5, which was not optimal for the pro-
tein stability from ProteoPlex assays. Different binding and elution conditions at pH6.8
and pH 8.2 were suggested for greater stability. New binding and elution buffers were
incorporated in the purification and better homogeneity of the particles were seen in the
negative stain as well as cryo-EM image. The particles looked intact with similar size
and a clear background was seen. This enabled cryo-EM data data to be collected and
single particle analysis to be performed for LRRK2 and LRRK1, which resulted in final
3D reconstruction produced at a resolution of 24.2A˚ and 24.3A˚ for LRRK2 and LRRK1
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respectively. Although, at low resolution, this is the first reported full-length structure
for LRRK2 and LRRK1. The dimeric arrangement of both the proteins is confirmed.
Both the complexes, have very similar overall shape forming elliptical homodimers with
each monomer having a concave shape. The convergence of the 3D refinement to low
resolution final maps for LRRK2 even with a bigger cryo-EM data, highlights the high
degree of flexibility within the protein complex and controlling the conformational di-
versity of the complex by binding with a substrate will be imperative for further high
resolution cryo-EM steps. This was further confirmed by the GTP-GDP bound LRRK2
negative stain analysis. In conclusion, we present the first structural insight into full
length LRRK2 as well as LRRK1, which will further assist follow-up work towards a
high-resolution structure of these important molecules.
Mutations in the LRRK2 gene are the greatest known genetic contributor to Parkin-
son’s disease. Today, LRRK2 is seen as promising target to treat Parkinson’s disease
by several research groups around the world. Pharmaceutical companies are developing
LRRK2 kinase inhibitors to correct the effects of most common PD related mutations.
The field has made enormous progress since the discovery of LRRK2 mutations in 2004.
The understanding of the genetic basis of this disease has increased exponentially since
this time but the elucidation of the precise atomic structure of this complex, and the
dynamics of this interaction in a functional context, remain a huge challenge. We be-
lieve this study will foster the structural elucidation of LRRK2 dimeric complex at high
resolution by Cryo-EM. With the technological improvements in Cryo-EM field, its is
now possible to routinely achieve resolutions that are sufficient to visualize side-chain
densities and to determine de novo atomic structure. But the major bottleneck for at-
taining high resolution cryo-EM maps still remains the biochemical sample preparation
for flexible and dynamic protein complexes. Therefore the next challenge towards high
resolution cryo-EM data collection for LRRK2 and LRRK1 would be address the inher-
ent conformational flexibility. LRRKs are special protein having two catalytic domains a
GTPase and a Kinase. Without a known substrate, it is necessary to use GTP/GDP to
stable the different conformational states of the protein. Our results with GTP and GDP
bound LRRK2 reveals improvement in the particles shape in negative stain EM. The
next step, should be to collect cryo-EM data and perform single particle on these stabled
GTP/GDP bound LRRK2 and compare the 2D class averages. If the conformations are
stabilized, it is possible to infer high resolution informations which are not blurred out
in averaging. Another possibility is to use GTPgammaS, which is a non-hydrolyzable
(or slowly hydrolyzable) G-protein-activating analog of GTP. This can further improve
conformational heterogeneity in LRRK2 particles by locking a particular functional con-
formation for a longer period of time. Another approach that can be used to address the
conformational flexibility in LRRK2 is to target the kinase domain. There are several
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kinase inhibitors now known for LRRK2 and binding of these kinase inhibitors can be
tested to improve the stability of the protein for cryo-EM sample preparation and data
collection. A high resolution structure of LRRK2 and LRRK1 will answer a lot of open
questions related to pathobiology of LRRK2 linked mutation in PD.
The novel method of liposomal preparation used as a tool to study membrane protein
under buffer gradient extends the technique of electron crystallography. 2D crystalli-
sation can be intrinsically difficult to achieve for some membrane proteins. It requires
the screening of hundreds of different crystallization conditions and various membrane
protein do not form large crystals at all, which hinders the subsequent image processing.
On the other hand, reconstituting membrane proteins in small unilamellar liposomes is
a relatively feasible task. Different LPRs can be tested in parallel, which controls the
crystalline behaviour of membrane proteins embedded in liposomes, eg. liposomes at
higher LPR (10:1) tends to make membrane proteins semi-crystalline in densely packed
membranes. Our proposed method can be broadly applied to other membrane proteins
and the gradient across the membrane can be precisely controlled to suit the native
environment of the purified membrane protein.
The next challenge that still needs to be tackled to prove this technique as a viable alter-
native to classical electron crystallography is the computational image processing of the
crystalline vesicles of membrane proteins. The crystal unbending and Fourier filtering
methods routinely used for electron crystallography are well established and works well
in cases where flat well-ordered 2D crystals are available and high resolution structure
determination is possible. However, these methods are limiting when applied to 2D
crystals that are badly ordered or non-flat. One approach to deal with these badly or-
dered non-flat 2D crystals of membrane protein is to treat them as single particles while
still exploiting neighbourhood correlation between adjacent proteins in the 2D crystal to
address the low signal to noise ration of the 2d crystal images. This method was success-
fully applied to improve resolution and higher structural details for MloK1 dataset and
incorporated as a part of inhouse 2dx software (Scherer et al. 2014). The single particle
approach can be applied to the proteoliposomes as well but there the algorithm has to
take into consideration two additional aspects, the spherical geometry of the liposomes
and the presence of overlapping lattice in the collected cryo-EM images of proteolipo-
somes. The position of a membrane protein on the spherical vesicles can be directly used
to determine two of the three Euler angles of orientation. As the sphericity of the vesicles
can be maintained during vitrification, this method simplifies orientation determination
which is usually difficult for small membrane proteins in projection matching routines
used in single particle reconstructions.The presence of two layer of lattice coming from
the upper and lower hemisphere of the vesicles respectively in the projection images of
the proteoliposomes has to be dealt by the software by deconvolution of signal coming
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from both lattices. Another possibility is to combine the single particle approach with
electron tomography and and sub-volume averaging. The goal here would be record the
same proteoliposomes such that the crystal unit cell from the image recorded by single
particle can be localized in the tomogram subsequently recorded by electron tomogra-
phy. A similar approach was demonstrated to work for COPI coated vesicles (Faini
et al. 2012). With the improvements in direct electron detectors and softwares, elec-
tron tomography and sub-volume averaging have been drastically improved and used
to reconstruct sub-nanometer resolution structures (Schur et al. 2013; Bharat et al.
2015). The in house developed Dynamo software system provides the necessary tools to
pick up individual 3D sub-volumes by exploiting the the regular arrangement of mem-
brane proteins in the crystalline proteoliposomes and perform sub-tomogram averaging
(Castao-Dez et al. 2012). Although, the resolution limit of this method will be lower
than that of X-ray crystallography but the advantage of providing a more native envi-
ronment to the membrane proteins, structure/function relationships can be probed by
the effect of buffer gradient. These low resolution dynamic snapshots of the membrane
protein can be combined to higher resolution X-ray diffraction (XRD) data, to model
the protein function efficiently.
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